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General Introduction and 





The alveolar bone is the main supporting tissue for teeth [1]. Sufficient 
alveolar bone volume and favorable architecture are essential in case 
of tooth loss and subsequent prosthetic rehabilitation. However, 
defects in alveolar bone can occur and are associated with tooth 
extraction, periodontal disease, peri-apical pathology, and trauma. 
Such alveolar bone defects can form a significant clinical problem [2].
The vast majority of alveolar bone defects can heal spontaneously by 
the natural process of bone regeneration under suitable physiological 
conditions because of the bone's ability to repair. However, the healing 
process of bone might be uncompleted and hampered, because 
several factors can challenge bone regeneration. For example, large 
defects, also known as critical bone defects, are not supposed to heal 
spontaneously by the inherent regenerative capacity of bone tissue 
due to the size of the defect [3]. Also, the patient’s medical condition 
can interfere with natural bone healing. Therefore, bone grafting is 
used as an approach to replace lost bone [4, 5].
Bone grafting is a surgical technique based on the use of natural or 
synthetic biomaterials to stimulate bone regeneration in an osseous 
defect [6]. The main function of the biomaterials is to promote the 
bone regrowth. Both natural and synthetic bone grafting materials 
are associated with advantages as well as disadvantages. Therefore, 
there is a continuous search to improve the bone grafting technique to 
regenerate defective bone.
Normal healing of alveolar bone
Bone healing is a complex, well-orchestrated, physiological process 
involving interactions between different cell types (e.g. hematopoietic 
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and immune cells, vascular and skeletal cell precursors) and proteins, 
as well as the expression of different genes that regulate the 
restoration of bone tissue function and structural integrity [7]. The 
stages of bone repair usually recapitulate the stages of skeletal 
development [8].
The repair of bone can be classified into three distinct phases: 
inflammation, proliferation, and remodeling [9] (Figure-1). The 
inflammatory phase is mediated by a cascade of growth factors, 
including transforming growth factor-β (TGF-β), fibroblast growth 
factor (FGF), platelet growth factor (PDGF), insulin-like growth factor-1 
(IGF-1), interleukins, vascular endothelial growth factor (VEGF), and 
bone morphogenic proteins (BMPs). These factors, released in 
response to the osseous insult, help to migrate, recruit, proliferate and 
differentiate mesenchymal stem cells into osteoblasts, chondrocytes, 
adipocytes, and endothelial cells [9, 10]. The result of the inflammatory 
phase is the formation of a primitive callus. This callus is organized 
further during the proliferative, or fibroplasia, phase. A periosteal 
response occurs during the proliferative process, which leads to the 
replacement of the primitive callus with immature woven bone by 
intramembranous or endochondral ossification [11] . During the final 
phase of bone repair, this irregular woven bone is converted into 
lamellar bone [12]. This involves replacement of the mineralized callus 
with mature mineralized bone and remodeling of bone back to its 
original shape and size. The final product of bone repair is an area of 




Figure 1: Schematic illustrating of the basic multicellular unit of the bone remodeling 
and cell communication.
Bone grafts and substitutes for bone defect treatment
Bone grafting stimulates healing of bone through three different 
mechanisms, i.e. osteogenesis, osteoconduction, and osteoinduction 
[13]. Osteogenesis means the osteo-differentiation and subsequent 
new bone formation by donor cells derived from either the host or 
grafts [14]. Osteoconduction refers to the ability to support the 
attachment of osteoblast and osteoprogenitor cells, and allows the 
migration and ingrowth of these cells within the three-dimensional 
architecture of the graft [15]. Osteoinduction describes that the graft 
can induce the primitive, undifferentiated and pluripotent cells to 
develop into the bone-forming cell lineage, by which osteogenesis is 
induced [15]. Clinically, the process of bone regeneration accomplished 
by bone graft implementation to restore bone defects (Figure-2).
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Figure 2: Clinical case of an edentulous ridge at the anterior site of maxilla treated 
with bone graft to increase the width of the site for proper prosthetic rehabilitation.
TypEs Of bONE GRAfTING mATERIALs 
(TAbLE 1)
Natural sources of bone grafts
Autologous bone grafts: An osseous graft harvested from an 
anatomic site avnd transplanted to another site within the same 
individual is called an autologous bone graft [14, 16]. An autologous 
bone graft can integrate into the host bone rapidly and completely, as 
it possesses osteogenic, osteoconductive, and osteoinductive 
properties [16]. Autologous bone grafting is regarded as the gold 
standard in treating bone defects and the benchmark in evaluating 
other bone grafts and substitutes. However, the drawbacks of the 




the harvesting process, including donor site complication and pain, 
increased blood loss, increased operative time, potential for donor site 
infection and limited volume of material available [14].
Allogeneic bone grafts: Allogeneic bone grafting refers to bone tissue 
that is harvested from one individual and transplanted to a genetically 
different individual of the same species [14, 16]. Given the limitation of 
autologous bone grafts, bone allografts are considered the best 
alternative and are successfully used in clinical practice, especially in 
patients with poor healing potential [16, 17]. Allografts are available in 
a variety of forms, including cortical, cancellous and demineralized 
bone matrix (DBM) [14].
Compared to autologous bone grafts, a similar but slower sequence of 
events happens in the incorporation process of allografts [16]. 
Allografts are found to be immunogenic. As a consequence, for safety 
reasons, frozen or freeze-dried products that are free of marrow and 
blood are commonly used [16]. Another issue in the use of allografts is 
the risk of viral transmission.
Xenogeneic bone grafts: Xenogeneic grafts are bone harvested from 
one species and implanted into a different species. The most 
commonly bone xenografts are obtained from porcine and bovine 
sources [13]. One of the most widely used bone xenografts in dentistry 
for the reconstruction of alveolar bone and maxillary sinus lifting is 
deproteinized bovine bone (DBB) [18] [19]. DBB contains only the 
mineral phase of bovine bone after complete removal of the organic 
components by using different purification techniques [20]. DBB is 
classified amongst the calcium phosphate (CaP) group of biomaterials, 
and has a chemical composition nearly identical to that of human 
bone [20].
6
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Synthetic bone substitutes
The shortage of autologous bone grafts and the impossibility to meet 
the demands in an aging population have triggered the blossoming of 
the bone biomaterials market [21]. Calcium phosphate (CaP) ceramics 
and CaP cements or combinations thereof are currently the most 
commonly synthetic bone substitutes available [22]. These materials 
have shown different mechanical properties and bone augmentation 
potential, which explains the common use of some material over 
others. Biomaterials based on CaP are claimed to be bioactive, to 
promote apatite formation and to bind directly to the bone after 
implantation [23].
CaP ceramics are a group of materials used for bone replacement 
because of the similarity of their chemical composition to the mineral 
phase of calcified tissues [22]. CaP ceramics have already been 
extensively tested in clinical studies [24].
Nowadays, the most frequently applied CaP ceramic is tricalcium 
phosphate (TCP), and more specific the rhombohedral β-form, 
β-tricalcium phosphate (β-TCP) [25]. With the chemical formula of 
Ca3(PO4)2, β-TCP has Ca/P ratio of 1.5, which is lower than that of 
hydroxyapatite and may partially explain its accelerated degradation 
and absorption [26]. TCP can be prepared with an interconnected 
porous structure that can directly benefit fibro- vascular invasion and 





Table 1: Overview of the different classes of bone substitutes graft materials in oral 
bone regeneration
Type of 









No potential for 





May heal large or 
small defects by itself 
Transplanting patient 
own bone forming 
cells to help heal the 
defect
Risk of pain 
and/or infection 
at harvest site 
which may last 





May not be an 














May heal small 
defects by itself 
Portions of the graft 
may turn into patient 
own bone





body cells to 
form bone 
Portions of the 
graft may 
remain in the 
body for years
Limited in its 
ability to heal 
large defects by 
itself
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ChALLENGED CONDITIONs fOR bONE 
REGENERATION
The healing process of bone can be challenged due to several 
local and systemic factors.
Local factors
Although bone possesses a good healing capacity, it may be limited/
insufficient under certain clinical situations such as large bone defects 
after high-energy trauma, revision surgeries, tumor resection, or 
osteoporotic fractures. The bone defect healing process is time 
consuming, and new bone development occurs gradually and can be 
hampered due to several factors; i.e. decreased blood supply, unstable 
biomechanical properties, un-favorable wound environment, and 
applied stress are major causes for bone healing impairment [3, 28]. 
Dental implants with bone augmentation are more prone to failure in 
patients with challenged bone conditions [29].
Systemic factors
The bone metabolism is affected in patients with metabolic and 
hormonal disorders. For instance, osteoporosis is one of the most 
frequently occurring bone disorders and characterized by low bone 
mineral density [30] and deterioration of bone tissue microarchitecture, 
caused by an unbalance in the amount of bone formed and resorbed 
during bone remodeling, which results in a net loss of bone over time 
[31] . Osteoporosis often occurs after menopause in women due to 
estrogen deficiency. Both animal experimental and clinical data 
reported that osteoporosis negatively influences the healing process 
of a bone defect [32]. The bone healing potential of osteoporotic 
patients is impaired due to reduced ability of mesenchymal stem cells 
10
General Introduction and Objectives of the Thesis
1
(MSCs) to differentiate into osteoblasts and form new bone [33]. The 
reduction in the number of MSCs with osteogenic potential during 
aging has been suggested to contribute to the age-related reduction 
in number of osteoblasts [34].
AppROAChEs TO pROmOTE bIOLOGICAL 
pROpERTIEs Of bONE bIOmATERIALs
Biological factors and bone substitutes
Cellular activity in bone is regulated by growth factors and proteins 
that are naturally present in bone. Growth factors bind to receptors 
on the surface of osteoprogenitor cells and osteoblasts and have an 
effect on cell metabolism [35]. A lot of different growth factors are 
available, including transforming growth factor (TGF)-β, insulin-like 
growth factor (IGF, I and II), platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF) and the bone morphogenetic proteins 
(BMPs). The combination and simultaneous activity of different growth 
factors results in in a synergistic bone formation promoting effect. 
Growth factors have also been used to support bone generation in 
large bone defects. Researchers have been able to isolate, and in 
some cases synthesize these factors in large quantities and reapply 
them in concentrated amounts to accelerate bone healing by bone 
graft substitutes.
The most widely used osteogenic bioactive molecules are BMPs. Urist 
discovered in 1965 that demineralized bone matrix (DBM) was able to 
induce bone formation into an ectopic location due to the presence of 
BMPs in the DBM [36]. At present, there are at least 20 subtypes of 




beta (TGF-beta) superfamily, BMP-2 INFUSE Bone Graft (Medtronic, 
Minneapolis, MN) and BMP-7 (OP-1, Stryker Biotech Inc.) are the only 
proteins of the BMP-group that have been approved by the US Food 
and Drug Administration for some human clinical uses substitute. Both 
BMPs are produced by recombinant DNA technology. The potential of 
using RhBMP-2 and rhBMP-7 for treatment of maxillofacial has been 
reported in several studies [36-38]. Nevertheless, there is concern 
about the clinical safety of using BMPS and even life-threatening 
complications have been reported [39, 40]. In addition to safety, 
rhBMPs are expensive and the high cost form a limitation for their 
application in daily patient care [41].
In view of the above mentioned, the clinical use of growth factors to 
support bone healing has to be considered critical.
Cell-based bone regenerative constructs
Cell-based therapeutics, in which living progenitor cells are seeded in 
a biomaterial scaffold and implanted in a bone defect site, have also 
been proposed for bone regeneration. The cells mostly used are so-
called Mesenchymal Stromal Cells (MSCs), which are retrieved from 
bone marrow or fat tissue from the patient themselves. Also, other cell 
donor sites, such as dental-pulp and periodontal ligament, have been 
investigated for their use in the regeneration of maxillofacial bone 
defects. MSCs cells can differentiate in a wide variety of mesenchymal 
tissues, like bone and cartilage. Before seeding into the scaffold, the 
number of available MSCs is expanded in cell culture.
The efficacy of a cell-based approach to promote bone formation has 
been proven in various animal studies [42, 43]. However, many clinical 
studies using human MSCs with a scaffold material failed to heal bone 
defects and no sufficient amount of bone tissue was generated [29]. 
12
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Also, cell-based therapy for bone regeneration is associated with 
safety concerns about the expansion of the MSCs, high cost, possible 
immunological rejection, and a wide variability due to donor-related 
differences [44]. Most recently, the anticipated bone forming role of 
MSCs loaded in a cell-based constructs has been debated [45], as 
those MSCs have demonstrated not to directly participate in bone 
formation, but rather function as immune-modulators for relatively 
short periods upon implantation.
Anti-osteoporotic drugs for bone regeneration
Anti-osteoporotic drug treatment has been suggested to accelerate 
bone regeneration and to prevent complications related to bone 
augmentation procedures in osteoporotic conditions (Figure 3 and 
Table 2).
Anti-resorptive agents
Commonly used drugs for osteoporosis are Bisphosphonates (BPs), 
selective estrogen receptor modulators (raloxifene), estrogens, and 
calcitonins [46]. They inhibit bone resorption via targeting osteoclast 
cells and then mainly reduce the loss of trabecular bone connectivity.
Bisphosphonates (BPs): BPs are drugs that prevent the loss of bone 
mass and are used to treat osteoporosis and similar diseases. They 
inhibit the digestion of bone by encouraging osteoclasts to undergo 
apoptosis, or cell death, thereby slowing bone resorption. 
Mechanistically, BPs modify the bone remodeling through either a 
direct action on osteoclasts or through factors released by the 
osteoblasts, which inhibit the osteoclast function [47].  In this way, 
they can also be useful to enhance bone healing [48]. Several BPs have 




risedronate, pamidronate, ibandronate, and zoledronic acid [48].
BPs can be divided into two classes: nitrogen-containing and non-
nitrogen-containing; Nitrogen-containing bisphosphonates, like 
alendronate, zoledronate, and risedronate, are more potent in the 
inhibition of bone resorption. They have a 70-fold increased 
osteoclastic activity compared to the non-nitrogen- containing 
compounds such as etidronate [49].
Selective estrogen receptor modulators (raloxifene): Raloxifene is 
approved by the FDA for the prevention and treatment of osteoporosis 
in menopausal women [50]. This drug is a selective estrogen-receptor 
modulator that directly binds to estrogen receptors. Subsequently, it 
expresses a variety of estrogen-regulated genes in bone tissues, which 
are activating osteoblasts and inhibiting osteoclasts [51].
Estrogen: Estrogen therapy remains the more traditional treatment 
used to relieve menopausal symptoms [52]. Although estrogen 
replacement was also suggested to decrease bone resorption in 
women with osteoporosis [53], long-term hormonal therapy is no 
longer recommended because of an unfavorable risk of breast cancer 
and heart attack [54].
Calcitonin: is a hormone made by the thyroid gland and can reduce 
the bone resorption process by binding to specific receptors of the 
osteoclasts [55].
Anabolic agents
Antiresorptive medications are successful in reducing the loss of bone, 
but they generally show no ability to stimulate the process of bone 
formation. Therefore, bone anabolism can only be obtained with 
agents that induce bone formation by recruiting more osteoblasts and 
14
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increasing their activity [56]. An example of a bone anabolic stimulator 
is parathyroid hormone (PTH) [57]. In addition, the ability of strontium 
ranelate (SR) and statins to enhance bone formation has been 
suggested by several in vivo experiments, but there is still no 
substantial clinical evidence that they indeed provide an effective 
therapy for osteoporosis [58].
Parathyroid hormone (PTH): Recently, intermittent injection of human 
PTH, a 34-amino-acid fragment, has been proposed to increase bone 
formation [43]. PTH binds to osteoblasts and has an indirect on 
osteoclasts [59]. Considering its effect on osteoblasts, PTH stimulates 
the exit of replicating osteoprogenitor cells from the cell cycle and 
increases the number of osteoblasts by promoting the proliferation 
and differentiation of osteoblasts, activates lining cells, and delays 
osteoblast apoptosis [60]. Further, PTH affects the secretion of 
osteoprotegerin, which indirectly regulates osteoclast formation. At 
present, the anabolic effects of intermittent PTH are utilized for 
treatment of severe osteoporosis [61]. However, PTH is still expensive 
to manufacture, which limits its clinical use for osteoporosis treatment.
Strontium ranelate (SR): SR has been recently proposed as an effective 
therapeutic agent for osteoporosis [62]. The strontium salt contains 
two strontium atoms per molecule and a divalent ranelic acid. This 
agent is found to decrease osteoclast activity effectively and 
subsequently prevents bone resorption [58]. As an anabolic agent, SR 
shows in vivo a significant stimulation of bone anabolism and 
increased collagen synthesis [63]. The efficacy of SR was also studied 
in osteoporotic postmenopausal women. The results clearly indicated 





Statins: Statins have bone anabolic effects as described first by 
Mundy et al. [65]. They found that statins are acting through increased 
production of bone morphogenetic protein- 2 (BMP-2), which enhances 
osteoblastic bone forming activity. Simvastatin is one of the most 
commonly prescribed cholesterol lowering drugs. Thus, statin 
decreases cholesterol level and inhibits bone resorption by reducing 
osteoclastogenesis [66]. In turn, the balance of bone resorption and 
formation can be restored. For example, a study with bone defects 
created in the calvaria of ovariectomized mice showed that oral 
application of lovastatin or simvastatin increased the bone density 
significantly [67]. However, some studies have demonstrated that this 
effect is dose-dependent and high doses were related to increase the 
risk of osteoporosis [44].
Figure 3: Regulation of bone metabolism and mechanisms of action of anti-
osteoporotic drugs.
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Table 2: Overview of anti-osteoporotic drugs
Drug class Action mechanism Drug
Anti-resorptive agents
Bisphosphonate
Inhibition of osteoclast 
attachment to bone; Inhibition of 
osteoclast differentiation; 
interference with osteoclast 







Interaction with bone estrogen 
receptors, increasing trabecular 
bone mass
Raloxifene
Estrogen Decrease bone resorption Conjugated estrogen
Calcitonin
Increasing osteoblasts activity 




PTH peptides Activation of osteoblasts function Teriparatide




Increased production of bone 
morphogenetic protein- 2 
(BMP-2), enhances osteoblasts, 






Several of the above mentioned growth factors and anti-osteoporotic 
drugs (antiresorptive and anabolic) have already been used in pre-
clinical studies with different types of bone grafts (autograft, allograft 
and synthetic alloplast). The therapeutics were administered either 
locally and systemically in healthy as well as osteoporotic conditions. 
Besides bone formation, optimal regulation of osteoclast-mediated 
bone resorption is a crucial step in enhancing favorable graft 
remodeling. In these studies, the BPs alendronate and zoledronate 
were shown to be the most potent in inhibiting bone resorption both 
in vitro and in vivo [68-70]. In addition, the efficacy of local application 
of the anabolic agent simvastatin has been demonstrated for in situ 
bone regeneration and repair in vivo [71-73].
Accordingly, the goal of this thesis is to study the effect of the systemic 
administration of anti-osteoporotic drugs on bone formation in bone 
defects using an osteoporotic animal model.
18
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ObJECTIVEs Of ThE ThEsIs
In view of the controversy regarding the pharmacological benefit of 
anti-osteoporotic drugs in adjunction with bone regeneration 
procedures, further in vivo investigations are required to clarify their 
role on bone healing in grafted osseous defects in healthy and 
osteoporotic condition. Consequently, the overall goal of this thesis 
was to study the effect of an induced osteoporotic bone condition on 
bone regeneration and the effect of systemic administration of anti-
osteoporotic drugs in adjunction with bone grafting procedures. The 
following research questions were addressed in specific experimental 
set-ups:
1. Does altered bone metabolism due to osteoporosis affects bone 
regeneration related to bone-defect grafting in an established 
animal model?
2. What evidence is available in the literature on anti-osteoporotic 
drug efficacy toward bone regeneration in healthy and 
osteoporotic conditions through a systematic review and meta-
analysis of the available preclinical studies?
3. Does single or combined administration of alendronate and 
simvastatin via daily subcutaneous injections during 3 weeks upon 
bone grafting procedures improves bone regeneration in healthy 
and osteoporotic rats?
4. Does the time of treatment with zoledronic acid (ZA) relative to 
bone grafting procedures affects bone regeneration compared to 
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The aim of the present study was to evaluate the effect of osteoporotic 
induction after 8-weeks of initial healing of bone defects grafted with 
InterOss® granules in a rat model. Bone defects were created in the 
femoral condyles of 16 female Wistar rats (one defect per rat). The 
defects were filled with anorganic bovine bone (Inter-Oss) granules. 
After 8 weeks of bone healing, rats were randomly ovariectomized 
(OVX) or sham-operated (SHAM). At 14 weeks of bone healing, all 
animals were euthanized. Bone specimens were harvested and 
processed for histological and histomorphometric analyses to assess 
new bone formation (N-BF%), remaining bone graft (RBG%), and 
trabecular bone space (Tb.Sp%) within the defect area. After 14-weeks 
of bone healing, histological evaluation revealed a significant 
alteration in trabecular bone in OVX rats compared to SHAM rats. 
Osseous defects grafted with InterOss® granules exhibited less new 
bone formation in OVX rats (22.5% ±3.0%) compared to SHAM rats 
(37.7% ±7.9%). Additionally, the remaining Inter-Oss material was 
significantly less in OVX (23.7% ±5.8%) compared to SHAM (34.8% 
±9.6%) rats. Finally, the trabecular bone space was higher in OVX 
(53.8% ±7.7%) compared to SHAM (27.5% ±14.3%) rats. In conclusion 
within the limitations of this study, inducing an osteoporotic condition 
in rats after initial healing of a bone graft material negatively 
influences bone regeneration in the created bone defect.
Keywords: Osteoporotic condition, animal model, xenograft, bone 
regeneration
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INTRODUCTION
Dento-alveolar as well as cranio-facial bone defects can be the 
consequence of trauma by accidents or surgical interventions [1]. 
Several grafting approaches can be applied to successfully treat such 
bone defects [2]. For instance, autogenic bone grafting is considered 
the ‘gold standard’, but is associated with problems of availability and 
it needs a second surgical procedure [1, 3]. In contrast, allograft 
obtained from bone bank is easily available, but has a significant risk 
of disease transmission [2, 4]. Therefore, xenograft and synthetic bone 
substitutes are the most commonly used graft materials in dental 
clinics [4]. Among them, anorganic bovine bone (e.g. Bio-Oss or similar 
products) is perhaps the most widely used and considered as reference 
material by notified bodies involved in medical device registration [5, 
6].
Although anorganic bovine bone products perform well in healthy 
patients, limited information is available about their performance 
under compromised conditions, like diabetes and osteoporosis [7]. In 
patients suffering from these systemic diseases, bone healing can be 
very unpredictable [8]. As demonstrated in previous studies, an 
osteoporotic condition may delay bone healing, increase resorption of 
bone materials, and decrease the rate of bone ingrowth [9, 10]. A 
common observation associated with osteoporosis is that the bone 
formation by osteoblasts is decreased. This is in part due to the lower 
proliferation/differentiation rate of mesenchymal stem cells (MSCs) 
into mature osteoblasts [11]. Suppression of MSCs in osteoporotic 
bone can be the consequence of a decreased synthesis of specific 
osteogenic-related factors [11]. Further, an increased osteoclast 
activity is also commonly observed in osteoporotic bone [12].
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2 Despite available knowledge on osteoporosis, its influence on bone 
regeneration in relation to bone grafting is still less understood. In 
addition, no information is available about how osteoporosis affects 
bone regeneration in grafted defects if osteoporosis onset is after 
graft installation. In view of experimental procedures requiring 
osteoporotic conditions, several osteoporotic animal models have 
been described. For example, the ovariectomized (OVX) rat is 
commonly used model in osteoporosis-related research [9]. OVX 
animals exhibit loss of trabecular bone similar to humans. 
Furthermore, a diminished trabecular bone morphology in the femoral 
condyle has been confirmed in OVX rats by histological examination 
[13]. Therefore, this OVX rat model seems appropriate to be used in 
studies dealing with the healing of a bone defect in relation to an 
osteoporotic condition. Consequently, the purpose of this study was to 
utilize this animal model to investigate the effect of an osteoporotic 
condition on bone regeneration after initial healing of a bone defect 
using a bovine bone grafting material.
mATERIALs AND mEThODs
Experimental Animal Model
The present study was approved by the Animal Ethical Committee at 
King Saud University, College of Dentistry, Riyadh, Saudi Arabia 
(Approval No. 4/67/389683). All in-vivo experiments obeyed the 
guidelines (national and international) for animal care and conformed 
to the ARRIVE guidelines. The study sample comprised a total of 16 
healthy female Wistar rats (age ~12 weeks and weighing around ~250 
grams). The animals were housed under veterinary supervision in 
standardized rat cages (4 – 5 animals per cage), maintained in a 
laboratory environment with controlled temperature (22˚C - 24˚C), 
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2humidity (45% – 55%), and 12-hourly light and dark cycles. All the 
animals had ad libitum access to a standard rat chow diet and water.
Experimental Surgical Procedures
All experimental surgical procedures were performed under general 
anaesthesia (GA), by administering a single intraperitoneal injection 
comprising a combination of 0.2 mg/kg xylazine (Chanazine, Chanelle 
Pharmacuetical, Dublin, Ireland) and 0.5 mg/kg ketamine 
hydrochloride (Ketamine, Pharmazeutische Präparate, Giessen, 
Germany). Once the animal was anesthetized, the left leg was shaved 
and disinfected using Povidone-iodine 10% solution (Alphadin, 
MedicScience, Haryana, India). A longitudinal parapatellar skin 
incision, 2 cm in length, was made along the midline over the distal 
femoral condyle. The knee joint capsule was identified through blunt 
dissection of the skin flap and was incised longitudinally. The patellar 
ligament was elevated and retracted laterally for complete exposure 
of the knee joint and distal femoral condyle. Using surgical drills in a 
low speed rotary drill (800 RPM), along with saline irrigation as 
coolant, a cylindrical bone defect (3 mm in diameter and 3 mm in 
depth) paralleling the long axis of the femoral shaft was created in the 
intercondylar notch. Then, bone defect was filled with a xenograft 
material, particle size: 0.25 - 1 mm (InterOss®, SigmaGraft Inc., 
Fullerton, California, USA) (Figure 1). After placement of the graft 
material, the soft tissue layers and skin were closed with VICRYL™ (4-
0) polyglactin 910 resorbable sutures (Ethicon, Johnson & Johnson, 




Figure 1: Pictures of the surgical procedure, A, the femoral condyle exposed, and then 
B, bone defect filled with InterOss® material.
After 8 weeks of bone healing, rats were randomly ovariectomized 
(OVX) or sham-operated (SHAM), as previously described [13]. Six 
weeks later, animals were euthanized by CO2-suffocation. Bone 
specimens were harvested and processed for histological and 
histomorphometric evaluation. The timelines of experimental design 
are described in Figure 2.
Harvested bone specimens were fixed in 10% neutral buffered formalin 
solution. The samples were dehydrated in ascending concentrations of 
ethyl alcohol from 70% to 100% and subsequently embedded in 
poly(methylmethacrylate) (pMMA) resin. After polymerization, ~10-15 
µm thick serial transverse sections (perpendicular to long axis of 
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2femur) of the resin embedded specimens were made using a diamond-
coated hard-tissue microtome (Leica®, Microsystems SP 1600, 
Nussloch, Germany). The first section of each specimen was made 
about 1 mm below the bone surface and then sectioning was 
continued distally. All sections were stained with methylene blue and 
basic fuchsine, as described previously [14]. Three sections, at different 
levels, were selected for further histological assessment.
Figure 2: Experimental animal groups and timeline for surgical procedures and sacrifice 
in study animals. 
Histological specimen preparation and evaluation
Histological and histomorphometric evaluation were carried out using 
a light microscope (Aperio ImageScope, Leica Biosystems, USA). The 
histomorphometric analyses were done using a computer-based 
image analysis system (IMAGE-J 1.4, National Institute of Health, 
Bethesda, MD, USA). Blinded histomorphometric measurements were 
performed for the three selected histological sections per defect (at 
x10 objective magnification). First, a circular region of interest (ROI) 
with a 3-mm diameter equal to the created defect was identified 
(Figure 3). Then, within this ROI, the amount of new bone formation 
(N-BF%), residual graft material (RBG%), and trabecular bone space 




Figure 3: In the histological sections, (A) a 3-mm region of interest (ROI) was identified, 
then (B) quantitative measurements to assess new bone formation (N-BF%), remaining 
bone graft (RBG%), and trabecular bone space (Tb.Sp%) using ImageJ software.
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All quantitative data were expressed as mean ± standard deviation 
(SD). Statistical analyses were performed using InStat Statistical 
Program (Version 3.05, GraphPad Software, San Diego, CA, USA). An 
unpaired Student’s t-test was conducted to evaluate differences in the 
mean values between the two study groups. The level of significance 
was set at 95% (p<0.05).
REsULTs
Animal observations
Post-operative healing was uneventful in all animals and no 
complications were observed after the bone grafting and ovariectomy 
surgeries, except one rat (from SHAM group) that died due to GA 
complications.
Descriptive histological evaluation
Representative images of the histological sections are depicted in 
Figure 4. The histological sections of the OVX specimens revealed that 
the trabecular bone had an osteopenic appearance. The trabecular 
network was less dense and irregular compared to SHAM sections. At 
14 weeks, images showed a higher trabecular number and less 
intertrabecular spacing for SHAM compared to OVX bone specimens. 
In between the bone trabeculae, bone marrow-like tissue was 
observed characterized by the presence of mononuclear cells. As the 
bone tissue was stained pink, it could easily be discerned from the 
grafted InterOss® granules. More granules seemed to remain in the 




Figure 4: Representative histological images of pMMA sections (left panels) for SHAM 
and OVX at 14-weeks post-implantation and corresponding images at x20 magnifica-
tion (right panels); methylene blue and basic fuchsin staining. Within the ROI, images 
show the evident presence of new bone, remaining InterOss® material (yellow*) and 
trabecular bone space (Tb.Sp).
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InterOss® granules in the SHAM specimens were surrounded by 
abundant new bone formation, which was in direct contact with the 
graft material. Further, bone bridging was observed between 
InterOss® granules. The grafted granules seemed to be completely 
covered by newly formed bone. High magnification images of the OVX 
specimen showed less newly formed bone in the osseous defects. The 
bone defect was for the major part filled with bone marrow-like tissue. 
The bone marrow-like tissue in the OVX rats contained more fat cells 
and less plasma cells compared to SHAM rats. Frequently, only a very 
superficial layer of bone was present on the surface of the granules. 
Occasionally, even no bone at all was seen covering the granules. 
Further, light micrographs showed the frequent presence of osteoclast-
like cells at the interface between bone marrow-like tissue and 
granules (Figure 5). The images demonstrated also that some bone 
trabeculae in the OVX rats had an eroded appearance, which could be 
associated with the presence of osteoclast-like cells.
Histomorphometric evaluation
The results of the histomorphometric evaluation of osseous defects 
grafted with InterOss® granules are depicted in Table 1 and Figure 6. 
Data showed a significantly decreased amount of new bone formation 
(N-BF%) in OVX rats compared to SHAM rats (p<0.05). Additionally, the 
amount of remaining graft material (RBG%) was significantly less in 
OVX compared to SHAM (p<0.05). Finally, the mean of trabecular bone 





Figure 5: Representative histological images at higher magnification showing 
InterOss® granules (yellow stars) well integrated and completely covered with newly 
formed bone (NB) in SHAM rats (left panels). In OVX rats (right panels), eroded bone 
surface and osteoclast-like cells (black arrowheads) were present. Bone marrow-like 
tissue in OVX rats contained more fat cells (fBM) compared to the hypercellular bone 
marrow-like tissue (hBM) in the SHAM group.
38
Bone Response in Osteoporotic Rats After Initial Healing of Bone Grafting
2
Figure 6: Histomorphometric evaluation of the mean volume fractions of new bone 
formation (N-BF%, red bar), remaining grafting material (RBG%, blue bar), and 
trabecular bone space (Tb.Sp%, yellow bar) occupying the defects after the 14-weeks 
of healing. Statistical analysis showed significant difference between SHAM and OVX 
for all parameters (p<0.05).
Table 1: Quantitative histomorphometric data showing mean ±SD values for new bone 
formation (N-BF%), remaining bone graft (RBG%), and trabecular bone space (Tb.Sp%) 
in the two study groups.
SHAM (n=7) OVX (n=8)
New bone formation (N-BF%) 37.7 ±7.9* 22.5 ±3.0
Remaining bone graft (RBG%) 34.8 ±9.6* 23.7 ±5.8
Trabecular bone space (Tb.Sp%) 27.5 ±14.3* 53.8 ±7.7





The present study aimed to evaluate the effect of inducing an 
osteoporotic condition after 8-weeks of initial healing of bone defects 
grafted with InterOss® granules in a rat model. The results revealed 
greater new bone formation within osseous defects in healthy 
compared to osteoporotic bone conditions. On the other hand, 
reduction in the remaining graft material was greater in the 
osteoporotic bone condition. In addition, osteoporotic bone showed 
larger areas of soft tissue/marrow space compared to healthy bone.
Clinically, deproteinized bovine bone graft material is extensively used 
to repair osseous defects [6]. Multiple human clinical studies have 
already been performed and long-term data regarding the outcome of 
bone grafting procedures have been reported. For instance, Piattelli et 
al. [5] conducted a histological analysis in 20 patients treated with 
Bio-Oss up to 4 years of bone healing. They concluded that anorganic 
bovine bone is osteoconductive and promotes the successful long-
term outcome of bone grafting. Further, the results from a 6 year 
randomized-controlled clinical trial with bovine bone material by 
Stavropoulos and Karring [15] showed improvements in intrabony 
defect healing using radiographs and clinical assessment parameters.
The biological performance of deproteinized bovine bone grafts is 
widely investigated in preclinical studies using healthy animals [14, 16-
20]. These confirmed that bovine bone particles enhance bone 
regeneration, and its remnants can become integrated very well with 
the newly formed bone. In many histological studies, osteoblasts and 
osteoclasts were observed in conjunction with bovine bone particles 
as well as with the newly formed bone. Intimate contact between the 
implanted material and the newly formed bone was also commonly 
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2presented. For instance, van Houdt et al. [14] tested bovine bone (Bio-
Oss) implanted in femoral condylar bone defects in rats. At 12 weeks, 
new bone formation in direct contact with the Bio-Oss granules was 
observed. The remaining Bio-Oss granules were completely covered by 
new bone. In line with those observations, histological analysis in the 
present study demonstrated similar findings in the SHAM (healthy) 
animals using InterOss® bone granules after 14 weeks of healing 
(Figure 5).
Beside the grafted material, the bone condition is the key factor 
affecting the graft healing and its integration with new bone [9, 21, 
22]. In many clinical cases, the presence of osteoporosis is a major 
challenging condition in patients undergoing bone grafting surgery 
due to decreased capacity of bone regeneration [9, 23]. In a 
retrospective analysis of 49 patients, an alveolar bone grafting 
procedure was impaired in 11 patients due to an unfavourable bone 
condition (i.e. osteopenia) [23]. This is primarily due to estrogen 
deficiency, which negatively influences the bone metabolism [24]. 
Estrogen deficiency causes an imbalance in osteoblastic/osteoclastic 
processes and results in an increased breakdown of bone and a 
reduced bone formation [25].
In previous preclinical studies, ovariectomized rats were used to 
evaluate qualitatively and quantitatively the influence of estrogen 
deficiency on bone grafting [26, 27]. For example, Luize et al. [27] 
examined bone blocks to augment a mandibular defect in OVX rats. 
At 7, 14, and 28 days post-surgery, histological analysis showed a 
delay in the osteogenic activity and bone healing in OVX rats 
compared to SHAM rats. The majority of grafted materials in OVX 




Additionally, OVX rats exhibited significantly less new bone formation 
compared to SHAM rats.
In contrast, some other animal studies did not observe a significant 
effect in terms of new bone formation related to bone grafting in 
osteoporotic versus healthy animals [14, 28-30]. This discrepancy 
might be due to differences in the experimental design, animal model, 
type of biomaterials, bone defects, and evaluation periods. Therefore, 
it is difficult to establish direct correlations between these studies.
Despite the contradiction in previous studies, the present findings 
sustain an impaired regenerative potential of bone grafting in OVX 
animals. Differently, our study model was designed in such a way to 
replicate the effects of late-induced osteoporosis after the bone 
grafting procedure was performed. At 14 weeks of bone healing, the 
quality and quantity of bone formation (N-BF%) was significantly 
decreased in the osteoporotic rats, which indicates that bone 
formation in a bone defect can become compromised in an 
osteoporotic condition, as induced post-implantation. Nevertheless, 
the exact involved mechanism needs to be explored further in follow-
up studies.
Previously, it has been reported that a deficiency in estrogen receptor 
(i.e. ER-α and ER-β) expression contributes negatively to the 
regenerative potential in osteoporotic bone [31]. Likewise, osteoblast-
related gene expression (e.g. RUNX2, BMP2, COLLAGEN I, and 
OSTEOCALCIN) were significantly decreased in OVX animals in relation 
to bone-biomaterial regeneration [17, 32]. Further, the osteogenic 
differentiation of mesenchymal stem cells (MSCs) derived from 
osteoporotic bone was significantly altered [11]. This emphasizes the 
effect of intrinsic deficiencies in the regenerative capability of 
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Previous data also verified an increase of the adipogenic activation in 
the bone of OVX animals [32]. This seems to disrupt the normal 
osteogenic function within the bone tissue [33]. In agreement, we 
noticed more fat bone marrow with an hypocellular appearance in 
OVX rats compared to healthy control rats.
It is important to note that in the current study the amount of 
remaining graft material was significantly less in the osteoporotic 
bone conditions compared to healthy bone conditions. We suppose 
that this is caused by the observed increased presence of osteoclast-
like cells around the graft granules in the OVX animals. Also, we 
assume that the eroded surfaces of trabecular bone indicate 
hyperactivity of osteoclastic cells in osteoporotic bone compared to 
healthy bone. Usually, the remodelling of bone graft material occurs in 
multiple phases [32]. Bone graft resorption is initiated by the function 
of osteoclastic cells. Osteoclast activation is directly linked to 
osteoblast function [21]. Therefore, an imbalance of osteoclast/
osteoblast activities in osteoporotic bone is connected with the 
decreased bone formation and increased rate of resorption, which 
limits the potential of bone-biomaterial incorporation, as observed in 
our study.
The activity of osteoclastic bone resorption can be visualized by 
specific staining, i.e. tartrate-resistant acid phosphatase (TRAP) 
staining [17, 34]. Decalcification of bone specimens is required for the 
application of TRAP staining. TRAP staining cannot be performed 
using pMMA embedding. However, in our study, we were limited to 
examine the activity of osteoclastic cells via their TRAP expression due 




Consequently, osteoclasts could only be analyzed by histological 
appearance (i.e. relatively larger and multinucleated) at higher 
magnification (Figure 5). In addition, proper quantification of the 
number of osteoclasts was not feasible. This has to be considered as a 
limitation of our study design.
In view of the above mentioned, it is very relevant to take care of the 
potential implication of impaired bone regeneration in relation to 
bone grafting procedures in osteoporotic conditions. In these 
situations, a solution can be the development of bone graft material 
that prospectively promotes the bone healing outcome.
CONCLUsION
Within the limitations of this study, inducing an osteoporotic condition 
in rats after initial healing of a bone graft material negatively 
influences bone regeneration in the created bone defect. Further 
investigations are needed to explore the clinical implications of these 
findings.
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The aim of this review was to systematically assess bone regeneration 
by using antiosteoporotic drugs in adjunction with bone grafting 
compared with controls (bone grafting without the administration of 
antiosteoporotic drugs). The review also evaluated statistical 
differences in the effect between systemic and local routes of drugs. 
Also, the effect of type of drugs (anticatabolic vs. anabolic) was 
subevaluated. PubMed and EMBASE (via OvidSP) resulted in inclusion 
of 60 animal studies. The studies were assessed for reporting quality 
and risk of bias. Outcome data from selected studies were categorized 
as either experimental (bone grafting with the administration of 
antiosteoporotic drugs) or control. Meta-analysis of selected studies 
was done for these outcomes: histomorphometrical bone area (BA%) 
and micro-CT bone volume (BV%). In this review, several animal 
models (52 healthy, 6 osteoporotic, and 2 both conditions) were 
subjected to examine the effect of antiosteoporotic drugs on bone 
grafting, with a predominant use of rodent species. Assessment 
indicates poor reporting quality and unclear risk of bias in the majority 
of studies. Random-effects metaanalysis revealed a significant 
increase in overall BA% (mean difference [MD]: 2.6, confidence interval 
[CI]: 2.25 to 2.92) and BV% (MD: 0.12, CI: 0.05 to 0.19) due to 
osteoporotic drug treatment compared with controls. For subgroups, 
both routes of antiosteoporotic drug administration showed similar 
effects on BA%. In contrast, systemic antiosteoporotic drug 
administration led to significantly higher BV% (MD: 6.75, CI: 5.30 to 
8.19) compared with local administration (MD: 0.02, CI: -0.03 to 0.08). 
Further, administration of anabolic drugs significantly increased BA% 
(MD: 5.75, CI: 4.62 to 6.87) compared with anticatabolic drugs (MD: 
1.86, CI: 1.47 to 2.26). In conclusion, both histomorphometrical and 
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micro-CT scan analysis indicated an overall effect of using the 
antiosteoporotic drugs toward bone regeneration in adjunction with 
grafting. However, not all studies showed a positive effect and the 
present results need to be applied with care, as the included papers 
showed experimental heterogeneity for animal models. Further (pre)
clinical research is warranted to explore whether drug-based 
strategies can be an effective adjunctive with bone grafting.
Keywords: bone substitutes, bone graft, antiosteoporotic drugs, 
animal models
Impact Statement
The aim of this meta-analysis was to assess whether antiosteoporotic 
drugs can promote bone regeneration in adjunction with bone 
grafting by using preclinical animal models. Although the majority of 
included studies indicated poor reporting quality and unclear risk of 
bias, an overall positive effect of the antiosteoporotic drugs toward 




ANTIOsTEOpOROTIC DRUGs AND bONE 
GRAfTING
INTRODUCTION
Regenerative dentistry is aimed to restore damaged alveolar bone in 
both healthy and medically compromised patients [1]. The key step in 
bone tissue regeneration is to stimulate a cascade of healing events, 
which can promote bone quantity and quality [2]. The use of bone 
grafts is shown to positively affect bone regeneration, due to their 
ability to support clot development and bone formation [2-4]. 
Multiple types of bone grafts are used for dental bone regeneration, 
including autologous bone, mineralized or demineralized allografts, 
animal derived xenografts, and synthetic bone substitutes [2, 5]. 
Although autogenetic bone grafting is the gold standard for bone 
regeneration, their routine use is restricted by limited availability, and 
the risk of post-operative complications, especially when harvested 
from the iliac crest [6, 7]. While bone allografts obtained from other 
individuals negate the limitations of autogenetic bone grafts, these 
have a risk of transmission of diseases [8].
The afore-mentioned drawbacks associated with autografts and 
allografts have motivated scientists and researchers to develop bone 
grafting materials, including calcium phosphate and bioactive glass 
(9, 10). For instance, hydroxyapatite (HA), tricalcium phosphate (TCP), 
and biphasic calcium phosphate (BCP) are commonly synthesized in 
the form of granules, blocks or cements [9, 11]. CaP-based materials 
are osteoconductive scaffolds and can integrate into the regenerating 
bone matrix [10, 11]. However, such alloplastic biomaterials are not 
capable to accommodate osteogenic cells and biological factors in situ 
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[10]. In addition, the clinical success of bone grafting depends on 
several sub-regulatory biological mechanisms controlled by hormones 
and specific tissue factors [12, 13], which can be compromised in 
systemic conditions affecting bone healing [14-16]. 
For instance, in healthy adults, a non-disturbed bone healing process 
will support the optimal integration of a bone substitute. However, 
osteoporotic conditions can decrease the potential for successful bone 
regeneration [15, 17-19]. This unfavorable effect can possibly be 
reversed by the adjunct administration of anti-osteoporotic drugs with 
bone substitutes for bone regeneration [20]. Consequently, a growing 
amount of research work involving anti-osteoporotic drug treatment 
and gonadectomy-induced osteoporotic animal models has been 
performed to evaluate the adjunctive role of these drugs in improving 
bone regeneration [15, 16, 20, 21]. 
The use of anti-osteoporotic drugs has been reported as an approach 
to favor early bone healing, through the creation of a physiologically 
conducive osteophilic environment, which enhances osteoblastic bone 
formation and slows down osteoclastic bone resorption [16, 22]. 
Consequently, research efforts currently widely use preclinical models 
to reveal effective strategies for the delivery of anti-osteoporotic drugs 
to a bone defect in both healthy and osteoporotic conditions [23, 24]. 
There are a number of anti-osteoporotic drugs that have anti-
catabolic effects (mainly bisphosphonates [BPs], calcitonin, and 
estrogen therapy) [23-25]. 
The anti-catabolic drugs can help to limit bone loss by decreasing 
osteoclastic activity. The second group of anti-osteoporotic drugs (i.e. 
anabolic agents) is expected to promote rapid bone formation, 




simvastatin [22-24, 26]. Mainly, statins are the drugs of choice in 
controlling high level of cholesterol by inhibiting a specific enzyme (i.e. 
3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase [27, 28]. 
Recently, several studies have explored an anabolic effect of statins on 
bone healing. Thus, statins have been widely investigated to evaluate 
their possible biological effectiveness in treating osteoporosis [26]. 
Although anti-osteoporotic drugs seem promising for in vivo bone 
regeneration, several issues related to their mechanism of action on 
bone healing need to be solved prior to the initiation of clinical trials. 
Nevertheless, there is a definitive preclinical data regarding the use of 
anti-osteoporotic drugs along with bone grafting procedures for 
enhanced bone regeneration.
For this reason, we attempted to systematically assess all the available 
preclinical publications showed an efficacy of anti-osteoporotic drugs 
on bone regeneration when used along with bone substitute materials 
in osteoporotic or healthy bone defect models. The meta-analyses 
focused on the primary quantitative outcome measures of 
histomorphometrical bone area (BA%) and micro-CT bone volume 
(BV%), as they are most common analytic methods for bone 
regeneration [29]. We further sub-evaluated the effect of route of 
drugs (systemic vs. local) and type of drugs (anti-catabolic vs. 
anabolic) on bone healing.
mATERIALs AND mEThODs
Database search strategy
An electronic search for relevant references was carried out in PubMed 
and EMBASE (via the Ovid platform) until 30th November 2018. Search 
terms were related to “anti-osteoporotic drugs” and “bone graft 
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substitutes”, and were identified by browsing the PubMed MeSH terms 
as well as EMTREE terms (EMBASE). The obtained search components 
were filtered for animal studies as previously defined (Supplementary 
Data S1) [30, 31].
Study selection
A bibliographic referencing software program (EndNote® X7, www.
endnote.com) was used to manage references and remove duplicate. 
Two independent reviewers (M.S. and A.B.) screened references 
independently and followed a Preferred Reporting Items for 
Systematic Reviews and Meta-analysis flowchart [32]. Titles/Abstracts 
were screened and excluded when: (1) not relevant to bone substitutes 
and anti-osteoporotic drugs, (2) in-vitro/ex-vivo studies or studies in 
humans, and (3) irrelevant animal model to osteoporotic or healthy 
conditions. 
Second, the full texts were selected as these inclusion criteria: (1) 
original research study in an animal model, (2) evaluation of bone 
regeneration under osteoporotic and/or healthy conditions, (3) 
implantation of bone graft substitutes along with anti-osteoporotic 
drugs, (4) clear description regarding site of implantation of bone 
substitute and the period of healing postoperatively, and (5) complete 
information regarding the type of anti-osteoporotic drugs used, its 
dosage, frequency, duration and route of administration. Papers were 
excluded when both reviewers were in agreement, and the reason for 
exclusion was recorded. Any pending disagreements were resolved 




Data collection and characteristics
From each study, data were extracted as follows (Supplementary 
Data S2): study title, name of authors, study design, animal model 
(species, gender, age, weight, number of animals, and medical 
condition), type of bone substitute, implantation site, and healing 
time; data related to anti-osteoporotic drugs (type, route, dose, 
frequency and duration), and findings for quantifying bone 
regeneration. The quantitative outcome measures included 
histomorphometrical bone area (BA%) and micro-CT bone volume 
(BV%).
Assessment of reporting quality and risk of bias
Quality of studies and risk of bias were assessed by using the SYRCLE 
risk-of-bias tool [33]. None of the studies were excluded from the 
systematic review or meta-analysis because of this quality appraisal. 
First, we assessed two indicators for reporting quality: randomization 
and blinded assessment. For these two items, ‘yes' score indicated 
“reported” and ‘no' score indicated “unreported”. Second, the 
assessment of risk of bias comprised selection bias, performance bias, 
detection bias, and attrition bias. Studies were scored ‘yes' for low risk 
of bias, ‘no' for high risk of bias, and ‘?' for unclear risk of bias. 
Meta-analyses for the included studies
Mean, standard deviation (SD), and numbers of implantation sites 
were extracted from the individual studies, for both BA%, BV%. When 
findings of an included study were presented in graphs, ImageJ (1.46r; 
National Institutes of Health, Bethesda, MD) was used to measure the 
mean and SD. In a minority of the included studies, the mean and SD 
were recalculated based on the median, range and the sample size. 
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Also, a few studies reported only the mean and 95% confidence 
interval (CI), and the SD was recalculated using the equation:
Standard deviation = √N  ×(Upper limit-Lower limit) ÷ 3.92 [34].
Then, the overall effect of anti-osteoporotic drugs on bone substitute 
integration was analyzed by making a comparison between the 
experimental and control groups. Also, we compared the effect of 
different drug routes (systemic vs. local) and different types of drugs 
(anti-catabolic vs. anabolic) on bone substitutes healing. Systemic 
route can be through the gastrointestinal tract, intravenous, 
intramuscular, intraperitoneal, or subcutaneous. Drugs can be also 
delivered at the implantation site (referred to as local route). When 
several treatment groups used the same control group in a study, the 
groups were treated as independent comparisons. We computed the 
proportion of shared samples by dividing the number in the control 
group by the number of comparisons. 
Review Manager 5 software provided by the Cochrane Collaboration 
(RevMan 5) was used to perform the meta-analysis. Heterogeneity 
was assessed by using the I2 metric, and the meta-analyses used 
random-effects modeling. Mean differences (MDs) with corresponding 
95% CIs were used to present the effect sizes. Differences between 
groups can be considered statistically significant when there are no 







The electronic search returned 1133 references (from PubMed) and 
1389 references (from Embase via Ovid) (Figure 1). Duplicates were 
removed and resulted in 1603 unique titles. Then, titles/abstracts were 
initially screened. As a result, 235 articles were identified for full text 
screening. Based on the inclusion and exclusion criteria, 60 articles 
were finally subjected to evaluation, data extraction, and 
interpretation for a meta-analysis.
Study characteristics
The complete list of the included studies and their characteristics can 
be found in Supplementary Data S3. Several types of animal models 
were used including: mice in 2 studies, rats in 38 studies, rabbits in 13 
studies, pigs in 2 studies, dogs in 2 studies, goats in 1 study, and sheep 
in 2 studies. In 52 studies, animals with healthy conditions were used. 
Osteoporotic conditions were reported only in 6 studies, and they 
mainly used the rat model. Evaluation of both healthy and 
osteoporotic animal models was reported in 2 studies. Multiple 
anatomical sites (tibia, femoral condyle, humerus, lumbar vertebra, 
calvarium, muscle pouch, femur, radius, mandible, and maxilla) were 
reported for placement of bone substitutes in the different studies. 
The period of implantation was 1 week as the shortest period as and 
12 weeks as the longest implantation time. Nevertheless, the majority 
of the studies evaluated the bone defect healing ranging from 4 to 8 
weeks. Several differences were observed between studies regarding 
systemic versus local route of drugs. In 32 studies, anti-catabolic drugs 
(BPs: alendronate, pamidronate, zoledronate, and ibandronate) were 
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investigated. The remaining 28 studies reported the effects of PTH, 
strontium ranelate, and simvastatin as anabolic drugs.
Figure 1: Flow-chart of the systematic search of literature and the process of study 





Methodological quality of studies
In Figure 2, reporting quality and risk of bias are presented. Blinding 
at any level of the experiment was mentioned only in 30% of the 
included articles. Randomization was reported approximately in 38% 
of the included articles. No details on the method of randomization 
were described in the majority of the included articles. Therefore, we 
were not able to assess the adequacy of randomization. The majority 
of the included studies scored ‘‘unclear risk’’ for selection bias, as 
there was no information available regarding the sequence of 
allocation, possibility of baseline differences and details of 
concealment. Less than 10% of the studies provided information 
regarding performance bias and among them 2% of the included 
articles revealed ‘‘high risk’’ of performance bias. 
Only a limited number of included articles reported that the animals 
were housed randomly during the experiment and/or that the 
caregivers/investigators were blinded from the experimental design. 
Almost 5% of the included articles showed ‘‘high risk’’ of performance 
bias, as the investigators had not performed a blinded experiment. It 
was not possible to access performance bias in the remaining studies 
due to a lack of information. 
In terms of evaluation for detection bias, >80% of the included articles 
did not provide details on animal randomization for the outcome 
assessment. Moreover, <30% of the included articles had conducted 
blinded outcome assessment, which showed ‘‘low risk’’ of detection 
bias. Also, ~30% of the included articles reported complete outcome 
data and scored ‘‘low risk’’ of attrition bias. Still, determining whether 
any information related to outcomes was missing from the remaining 
studies was difficult, as frequently the total number of animals used 
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was unclear (i.e. how many animals were enrolled initially and were 
these the same as those at the end of the implantation period?).
Figure 2: Bar chart showing (A) the assessment of study-quality and (B) risk of bias for 
the included 60 papers. The first two items are the key study-quality indicators; ‘‘yes’’ 
score indicating reported, and ‘‘no’’ score indicating unreported. The other items 
assessed risk of bias; ‘‘yes’’ indicating low risk of bias, ‘‘no’’ indicating high risk of bias, 
and ‘‘unclear’’ risk of bias.
Quantitative data synthesis (meta-analysis)
All 60 included articles were used for meta-analysis. An overview of 
the data obtained through meta-analyses is depicted in (Table 1), 
Figure 3 and Supplementary Data S4 (forest plots). In addition, the 
total numbers of comparisons that revealed positive effect (+ve), 




Overall effect of anti-osteoporotic drugs on bone substitute healing. In 
80 comparisons, 1289 defects were used to estimate the overall effect 
of anti-osteoporotic drugs on bone substitute healing based on BA% 
as the outcome variable (Table 1). Out of these, 51 comparisons 
showed a positive effect, 8 comparisons showed a negative effect, and 
21 comparisons showed no effect (Table 2). Similarly, for BV% as the 
outcome variable, 996 defects were enrolled in 72 comparisons (Table 
1). Positive effects were observed in 40 comparisons, 6 comparisons 
showed a negative effect and no effect was observed in 26 
comparisons (Table 2). 
The overall results showed a significant effect of anti-osteoporotic 
drugs on bone regeneration after bone grafting compared with the 
control groups (Figure 3), as quantified by BA% (MD: 2.58%, CI: 2.25-
2.92) and BV% (MD: 0.12%, CI: 0.05-0.19). The heterogeneity for the 
overall analyses for BA% and BV% was very high, with I2 values of 97% 
and 95% respectively (Table 1).
Route of anti-osteoporotic drug administration. For BA%, systemic 
versus local routes of drug administration showed no significant 
differences (Table 1; Figure 3). However, BV% as an outcome showed a 
statistically significant effect of systemic drug administration over 
local administration. For the subgroup analysis, heterogeneity was 
very high (Table 1). This did not help to explain the high level of 
heterogeneity in the overall analyses.
Type of anti-osteoporotic drugs. As in Table 1 and Figure 3, it was 
observed that the anabolic drugs significantly increased BA% and 
BV% compared with anti-catabolic drugs. For the subgroup analysis, 
heterogeneity was very high (Table 1). This did not help to explain the 
high level of heterogeneity in the overall analyses.
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Overall 80 1289 2.58 [2.25, 2.92] 97%
Route of administration
Systemic 23 424 2.24 [1.67, 2.82] 95%
Local 57 882 3.23 [2.72, 3.73] 98%
Type of drug
Anti-
catabolic 45 807 1.86 [1.47, 2.26] 98%














) Overall 72 996 0.12 [0.05, 0.19] 95%
Route of administration
Systemic 34 442 6.75 [5.30, 8.19] 95%
Local 38 554 0.02 [-0.03, 0.08] 94%
Type of drug
Anti-
catabolic 32 433 0.00 [-0.06, 0.06] 94%
Anabolic 40 563 1.76 [1.38, 2.15] 95%
Effect estimate meta-analysis presented as mean difference (MD) and 95% confidence 
interval (CI) according to overall route of administration, and type of drug. 
BA%, histomorphometrical bone area; BV%, micro-CT bone volume; CI, confidence 




Figure 3: Forest plots for an overview of the data obtained through meta-analyses: (A) 
BA% and (B)  BV%. BA%, histomorphometrical bone area; BV%, micro-CT bone volume; 
CI, confidence interval; IV, intervention.
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Table 2: total numbers of comparisons measured for each outcome variable and 
showing  positive effect (+ve), negative effect (-ve), or no effect.










Bone Area (BA%) 80 51 8 21
Micro-CT bone volume 
(BV%) 72 40 6 26
Bias in publication 
Figure 4 shows an asymmetry in funnel plot for the outcome variable 




Figure 4: Funnel plots for the data obtained through meta-analyses: (A) BA% and (B) 
BV%. The vertical line indicates the random-effect estimate (I2 > 94%). MD, mean 
difference; SE, standard error.
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DIsCUssION
In this study, we attamptted to evaluate the beneficial role of adjunct 
administration of anti-osteoporotic drugs in bone defect regeneration 
with the use of bone substitutes in animal models with osteoporotic or 
healthy conditions. The present findings should be utilized with much 
care because of poor reporting quality and unclear risk of bias in the 
majority of the included articles. Based on meta-analyses, both 
histomorphometrical and micro-CT scan analysis indicated an overall 
positive effect of the anti-osteoporotic drugs towards bone 
regeneration related to bone grafts. However, not all studies showed 
a positive effect and the statistical heterogeneity (I2= 97%) was very 
high. We looked for possible explanations of this variations in studies 
by conducting subgroup analyses based on the route and type of 
drugs.
Indeed, the administration of anti-osteoporotic drugs showed a 
positive effectiveness on BA% as observed in 51 out of 80 comparisons, 
primarily involving rat models [20, 21, 35-38]. Also, 40 out of 72 
comparisons showed positive effects of anti-osteoporotic drugs on the 
BV% [9-41]. In contrast, several studies in the present meta-analysis 
indicated negative zero effects of the administration of anti-
osteoporotic drugs to enhance new bone formation by bone grafts 
[42, 43]. For example, Jakobsen et al. [42] showed a remarkable 
diminish in bone formation within bone graft treated with anti-
osteoporotic drug (i.e. BP). They assumed that because BP slows down 
resorption rate of the graft material, it thereby impairs bone 




Also, Kamo et al. [43] found that PTH administration had no effect on 
bone regeneration related to bone grafts in healthy compared with 
osteoporotic animals. Therefore, results should be interpreted with 
caution, and it is inconclusive as to whether the benefits of 
administration of anti-osteoporotic drugs on bone regeneration 
related to bone grafts can be translated to clinic or not. In addition, 
more investigations are still indicated.
Regarding subgroups analyses, this meta-analysis aimed at comparing 
systemic versus local delivery and whether these administration routes 
affect bone regeneration related to bone grafts differently. 
Interestingly, the significant increase in BV% was mainly associated 
with the systemic administration of anti-osteoporotic drugs. This could 
be attributed to the ability of micro-CT scans to evaluate bone volume 
in a three-dimensional mode compared with the two-dimensional 2D 
histology as previously suggested [29]. 
On the other hand, the effect of anti-catabolic versus anabolic drugs 
on bone defect healing was sub-evaluated. We found that the use of 
anabolic drugs results in an increased BA% and BV% compared with 
anti-catabolic drugs. A likely explanation is the fact that anabolic 
drugs can promote bone healing by recruiting and activating more 
osteoblasts at the site of bone healing, while anti-catabolic agents 
prevent bone breakdown [44]. Although their molecular mechanisms 
are not clearly understood, anabolic drugs have been used as an 
adjunct to support bone fracture healing [44]. These drugs were 
originally intended to reverse bone loss in osteoporosis by altering 
bone metabolism [45]. Still, their mechanism of action on bone defect 
healing in combination with bone grafts is not completely understood.
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Driven by the fact that the biological benefits of anti-osteoporotic 
drugs on the bone healing of bone grafts are affected by, for example, 
the size of bone defect, regenerative capacity, bone graft volume, 
condition of bone metabolism, and pharmacokinetics of the drugs 
[38], a growing number of investigations have been conducted in the 
animal model. Therefore, the present systematic review was based on 
a comprehensive search for evidence and high level of consistency in 
data collection and interpretation. 
Nevertheless, the findings need to be interpreted with care; as the 
papers included here showed experimental heterogeneity for the 
animal model (rats, rabbits or sheep), the methods applied for 
osteoporosis induction, the numbers of animals, the surgical site and 
techniques, the chemical composition of used bone substitutes, the 
healing period, the type of anti-osteoporotic drugs and route of 
administration (systemically injected or locally mixed with the bone 
substitute). For instance, several animal models studied the benefit of 
anti-osteoporotic drugs [46] on bone regeneration, with a predominant 
use of rodent species. 
Although data were reported from both healthy (52 studies) and 
osteoporotic animals (6 studies), two studies [20, 41] were only 
specifically designed to examine the effect of anti-osteoporotic drugs 
on bone regeneration related to bone grafts in a direct comparison by 
using both animals with osteoporotic conditions and healthy animals 
in one single study. Similarly, the nature of the used bone graft 
materials was not considered for meta-analysis. A variety of graft 
materials (synthetic and non-synthetic) was used, including bioactive 
glass, calcium phosphate cement, calcium sulfate, HA, TCP, and 




It should be mentioned that in a previous meta-analysis [47], there 
was no superiority of autografts bone over other bone materials with 
regard to survival and quality of bone grafts in the augmented areas. 
In addition, the action of different bone materials has a direct effect 
on bone healing and formation. This is due to differences in their 
biological behavior and rate of resorption, which mainly depends on 
their physical and chemical properties [9,43].
For radiographical (micro-CT scan) assessment as an outcome 
parameter, it needs to be emphasized that such examination does not 
correlate well with the histological evaluation of a bone defect grafted 
with radiopaque bioceramics [29]. Thus, a radiographical scan has 
limited importance in the investigation of bone regeneration related 
to bone grafts, because it has low accuracy in discriminating newly 
formed bone from bioceramics material with the bone defect. 
Therefore, it can be concluded that the radiographic analysis of bone 
grafting procedures requires histological confirmation.
Finally, the reporting quality of the included articles as well as the 
possibility of publication bias cannot be neglected. Because of the 
poor general reporting on randomization and blinding, we were 
unable to indicate whether the risk of bias in the included articles was 
low. As such, the risk of overestimating the true effect of anti-
osteoporotic drugs on bone regeneration related to bone grafts is 
substantial. To prevent such bias in preclinical studies, researchers are 
recommended to pursue maximal reporting transparency by following 
ARRIVE guidelines. These guidelines are considered key to ensure 
reproducibility of animal research and to guide the collection, analysis, 
and presentation for in vivo databases [48].
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CONCLUsIONs
There was an overall improvement of bone regeneration with bone 
substitutes as a result of adjunctive administration of anti-
osteoporotic drugs, in terms of both histomorphometrical bone area 
and micro-CT bone volume as outcome parameter. However, not all 
studies showed a positive effect and the findings need to be 
interpreted with much caution, as the included articles showed 
experimental heterogeneity for the majority of studies. Further (pre)
clinical investigations are demanded to explore whether drug-based 
strategies can be an effective adjunctive with bone grafting. 
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Supplement	  1:	  Search	  Strategy	  
	  
Subject	  (1):	  Anti-­‐osteoporotic	  drugs	  
	  
PubMed	  
"anti-­‐osteoporotic"[tiab]	  OR	  "antiosteoporotic"[tiab]	  OR	  "simvastatin"[tiab]	  OR	  Hydroxymethylglutaryl-­‐CoA	  Reductase	  
Inhibitors	  [mesh]	  OR	  "statins"[tiab]	  OR	  "statin"[tiab]	  OR	  "AMG	  162"[tiab]	  OR	  "denosumab"[tiab]	  OR	  zoledronate[tiab]	  
OR	  "zoledronic	  acid"[tiab]	  OR	  "Fareston"[tiab]	  OR	  "Forteo"[tiab]	  OR	  "Parathyroid	  Hormone"[tiab]	  OR	  
"Teriparatide"[tiab]	  OR	  "Nolvadex"[tiab]	  OR	  "strontium	  ranelate"[tiab]	  OR	  "Miacalcic"[tiab]	  OR	  "Fortical"[tiab]	  OR	  
"risedronate"[tiab]	  OR	  "pamidronate"[tiab]	  OR	  "olpadronate"[tiab]	  OR	  "ibandronate"[tiab]	  OR	  "Xydiphone"[tiab]	  OR	  
"Xidifon"[tiab]	  OR	  "Etidronate"[tiab]	  OR	  "Didronel"[tiab]	  OR	  "Etidronic	  Acid"[Mesh]	  OR	  "Ergocalciferol"[tiab]	  OR	  
"Calciferols"[tiab]	  OR	  "Ergocalciferols"[Mesh]	  OR	  "Bisphosphonate"[tiab]	  OR	  "Bisphosphonates"[tiab]	  OR	  
"Diphosphonates"[Mesh]	  OR	  "Disphosphonate"[tiab]	  OR	  "Disphosphonates"[tiab]	  OR	  
"Dihydroxycholecalciferols"[Mesh]	  OR	  "Calcamine"[tiab]	  OR	  "Tachystin"[tiab]	  OR	  "Dihydrotachysterin"[tiab]	  OR	  
"Dihydrotachysterol"[Mesh]	  OR	  "Bonefos"[tiab]	  OR	  "Clodronate	  Disodium"[tiab]	  OR	  "Clodronate"[tiab]	  OR	  "Clodronic	  
Acid"[tiab]	  OR	  "Clodronic	  Acid"[Mesh]	  OR	  "incadronate"[tiab]	  OR	  "cimadronate"[Supplementary	  Concept]	  OR	  
"Cholecalciferols"[tiab]	  OR	  "Calciol"[tiab]	  OR	  "Vitamin	  D3"[tiab]	  OR	  "Cholecalciferol"[Mesh]	  OR	  "Dietary	  Calcium"[tiab]	  
OR	  "Calcium,	  Dietary"[Mesh]	  OR	  "Soltriol"[tiab]	  OR	  "Silkis"[tiab]	  OR	  "Rocaltrol"[tiab]	  OR	  "Calcijex"[tiab]	  OR	  
"Calcitriol"[tiab]	  OR	  "Calcitriol"[Mesh]	  OR	  "Thyrocalcitonin"[tiab]	  OR	  "Calcitrin"[tiab]	  OR	  "Calcitonin"[tiab]	  OR	  
"Calcitonin"[Mesh]	  OR	  "Dedrogyl"[tiab]	  OR	  "Calderol"[tiab]	  OR	  "Hidroferol"[tiab]	  OR	  "Alendronate"[tiab]	  OR	  
"Fosamax"[tiab]	  OR	  "Osteoporosis/therapy"[Mesh]	  OR	  "Bone	  Density	  Conservation	  Agents"[Mesh]	  OR	  "Antiresorptive	  
Agents"[tiab]	  OR	  "Bone	  Resorption	  Inhibitors"[tiab]	  OR	  "Antiresorptive	  Drugs"[tiab]	  OR	  "Bone	  Density	  Conservation	  
Agents"[Pharmacological	  Action]	  OR	  "Selective	  Estrogen	  Receptor	  Modulators"[Mesh]	  OR	  "Alendronate"[Mesh]	  OR	  
"Calcifediol"[tiab]	  
Embase	  
exp	  Osteoporosis/dt,	  th	  OR	  exp	  Bone	  Density	  Conservation	  Agent/	  OR	  exp	  Diphosphonates/	  OR	  exp	  Coumestrol/	  OR	  
exp	  Equol/	  OR	  exp	  Genistein/	  OR	  exp	  Pterocarpans/	  OR	  exp	  Rotenone/	  OR	  exp	  Simvastatin/	  OR	  exp	  Statins/	  OR	  exp	  
iSoflavones/	  OR	  exp	  Antibodies	  Monoclonal	  Humanized/	  OR	  exp	  Estrogen	  Replacement	  Therapy/	  OR	  exp	  Selective	  
Estrogen	  Receptor	  Modulator/	  OR	  exp	  Parathyroid	  Hormone/	  OR	  denosumab.ti,ab.	  OR	  AMG	  162.ti,ab.	  OR	  
antiosteoporotic.ti,ab.	  OR	  zoledronate.ti,ab.	  OR	  24,25-­‐Dihydroxyvitamin	  D3.ti,ab.	  OR	  zoledronic	  acid.ti,ab.	  OR	  
Fortical.ti,ab.	  OR	  Forteo.ti,ab.	  OR	  Nolvadex.ti,ab.	  OR	  strontium	  ranelate.ti,ab.	  OR	  Miacalcic.ti,ab.	  OR	  risedronate.ti,ab.	  
OR	  pamidronate.ti,ab.	  OR	  olpadronate.ti,ab.	  OR	  ibandronate.ti,ab.	  OR	  Xydiphone.ti,ab.	  OR	  Xidifon.ti,ab.	  OR	  
Etidronate.ti,ab.	  OR	  Didronel.ti,ab.	  OR	  Calciferols.ti,ab.	  OR	  Bisphosphonate.ti,ab.	  OR	  Bisphosphonates.ti,ab.	  OR	  
Dihydrotachysterin.ti,ab.	  OR	  Bonefos.ti,ab.	  OR	  Clodronate.ti,ab.	  OR	  Disodium.ti,ab.	  OR	  incadronate.ti,ab.	  OR	  
Cholecalciferols.ti,ab.	  OR	  Calciol.ti,ab.	  OR	  Soltriol.ti,ab.	  OR	  Rocaltrol.ti,ab.	  OR	  Thyrocalcitonin.ti,ab.	  OR	  Calcitrin.ti,ab.	  
OR	  Hidroferol.ti,ab.	  OR	  Fosamax.ti,ab.	  OR	  Antiresorptive.ti,ab.	  OR	  Calcifediol.ti,ab.	  OR	  25-­‐Hydroxyvitamin	  D2.ti,ab.	  OR	  
Alendronate.ti,ab.	  OR	  Calcitonin.ti,ab.	  OR	  Calcitriol.ti,ab.	  OR	  Calcium	  Dietary.ti,ab.	  OR	  Clodronic	  Acid.ti,ab.	  OR	  
Dihydrotachysterol.ti,ab.	  OR	  Diphosphonates.ti,ab.	  OR	  Etidronic	  Acid.ti,ab.	  OR	  Raloxifene.ti,ab.	  OR	  Tamoxifen.ti,ab.	  OR	  
Teriparatide.ti,ab.	  OR	  Toremifene.ti,ab.	  OR	  Vitamin	  D3.ti,ab.	  OR	  Coumestrol.ti,ab.	  OR	  Equol.ti,ab.	  OR	  Genistein.ti,ab.	  
OR	  Pterocarpans.ti,ab.	  OR	  Rotenone.ti,ab.	  OR	  Simvastatin.ti,ab.	  OR	  Statins.ti,ab.	  OR	  iSoflavones.ti,ab.	  OR	  Parathyroid	  
















Subject	  (2):	  Bone	  substitutes	  
	  
PubMed	  
Biocompatible	  Materials[Mesh]	  OR	  Bone	  Cements[Mesh]	  OR	  Calcium	  Phosphates[Mesh]	  OR	  Silicates[Mesh]	  OR	  Bone	  
Transplantation	  [Mesh]	  OR	  Alveolar	  Bone	  Grafting[Mesh]	  OR	  Bone	  Substitutes[tiab]	  OR	  Bone	  Replacement[tiab]	  OR	  
Bone	  Replacements[tiab]	  OR	  Bone	  Replacement	  Material[tiab]	  OR	  Bone	  Replacement	  Materials[tiab]	  OR	  Calcium	  
Phosphate[tiab]	  OR	  Hydroxyapatite[tiab]	  OR	  Beta-­‐tricalcium	  Phosphate[tiab]	  OR	  Tricalcium	  Phosphate[tiab]	  OR	  
Tricalcium	  Orthophosphate[tiab]	  OR	  Bone	  Ceramic[tiab]	  OR	  Bone	  Ceramics[tiab]	  OR	  beta-­‐TCP[tiab]	  OR	  Dicalcium	  
Phosphate[tiab]	  OR	  Calcium	  Superphosphate[tiab]	  OR	  Bone	  Graft[tiab]	  OR	  Bone	  Grafts[tiab]	  OR	  Bone	  Grafting[tiab]	  OR	  
Bone	  Graftings[tiab]	  OR	  Osseous	  Graft[tiab]	  OR	  Osseous	  Grafts[tiab]	  OR	  Osseous	  Grafting[tiab]	  OR	  Synthetic	  Bone[tiab]	  
OR	  Synthetic	  Bones[tiab]	  OR	  Bioactive	  Glass[tiab]	  OR	  Bone	  Cement[tiab]	  OR	  Bone	  Cements[tiab]	  OR	  bone	  
xenograft[tiab]	  OR	  bone	  xenografts[tiab]	  OR	  bone	  allograft[tiab]	  OR	  bone	  allografts[tiab]	  OR	  Autologous	  Graft[tiab]	  OR	  
Autologous	  Grafts[tiab]	  
Embase	  
exp	  Biocompatible	  Materials/	  OR	  exp	  bone	  cements/	  OR	  exp	  bone	  graft/	  OR	  exp	  silicate/	  OR	  exp	  calcium	  phosphate/	  
OR	  calcium	  phosphate	  dibasic.ti,ab.	  OR	  calcium	  pyrophosphate.ti,ab.	  OR	  bone	  transplantation.ti,ab.	  OR	  bone	  
substitute.ti,ab.	  OR	  bone	  substitutes.ti,ab.	  OR	  bone	  artificial.ti,ab.	  OR	  bone	  replacement.ti,ab.	  OR	  bone	  
replacements.ti,ab.	  OR	  calcium	  phosphate.ti,ab.	  OR	  hydroxyapatite.ti,ab.	  OR	  beta-­‐tricalcium	  phosphate.ti,ab.	  OR	  
tricalcium	  phosphate.ti,ab.	  OR	  tricalcium	  orthophosphate.ti,ab.	  OR	  beta-­‐TCP.ti,ab.	  OR	  dicalcium	  phosphate.ti,ab.	  OR	  
calcium	  superphosphate.ti,ab.	  OR	  bone	  graft.ti,ab.	  OR	  bone	  grafts.ti,ab.	  OR	  osseous	  graft.ti,ab.	  OR	  osseous	  grafts.ti,ab.	  
OR	  synthetic	  bone.ti,ab.	  OR	  synthetic	  bones.ti,ab.	  OR	  bioactive	  glass.ti,ab.	  OR	  bone	  cement.ti,ab.	  OR	  bone	  
cements.ti,ab.	  OR	  bone	  xenografts.ti,ab.	  OR	  bone	  xenograft.ti,ab.	  OR	  bone	  allografts.ti,ab.	  OR	  bone	  autograft.ti,ab.	  OR	  
bone	  autograft.ti,ab.	  OR	  bone	  ceramic.ti,ab.	  OR	  bone	  ceramics.ti,ab.	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“animal	  experimentation”[MeSH	  Terms]	  OR	  “models,	  animal”[MeSH	  Terms]	  OR	  “invertebrates”[MeSH	  Terms]	  OR	  
“Animals”[Mesh:noexp]	  OR	  “animal	  population	  groups”[MeSH	  Terms]	  OR	  “chordata”[MeSH	  Terms:noexp]	  OR	  
“chordata,	  nonvertebrate”[MeSH	  Terms]	  OR	  “vertebrates”[MeSH	  Terms:noexp]	  OR	  “amphibians”[MeSH	  Terms]	  OR	  
“birds”[MeSH	  Terms]	  OR	  “fishes”[MeSH	  Terms]	  OR	  “reptiles”[MeSH	  Terms]	  OR	  “mammals”[MeSH	  Terms:noexp]	  OR	  
“primates”[MeSH	  Terms:noexp]	  OR	  “artiodactyla”[MeSH	  Terms]	  OR	  “carnivora”[MeSH	  Terms]	  OR	  “cetacea”[MeSH	  
Terms]	  OR	  “chiroptera”[MeSH	  Terms]	  OR	  “elephants”[MeSH	  Terms]	  OR	  “hyraxes”[MeSH	  Terms]	  OR	  
“insectivora”[MeSH	  Terms]	  OR	  “lagomorpha”[MeSH	  Terms]	  OR	  “marsupialia”[MeSH	  Terms]	  OR	  “monotremata”[MeSH	  
Terms]	  OR	  “perissodactyla”[MeSH	  Terms]	  OR	  “rodentia”[MeSH	  Terms]	  OR	  “scandentia”[MeSH	  Terms]	  OR	  
“sirenia”[MeSH	  Terms]	  OR	  “xenarthra”[MeSH	  Terms]	  OR	  “haplorhini”[MeSH	  Terms:noexp]	  OR	  “strepsirhini”[MeSH	  
Terms]	  OR	  “platyrrhini”[MeSH	  Terms]	  OR	  “tarsii”[MeSH	  Terms]	  OR	  “catarrhini”[MeSH	  Terms:noexp]	  OR	  
“cercopithecidae”[MeSH	  Terms]	  OR	  “hylobatidae”[MeSH	  Terms]	  OR	  “hominidae”[MeSH	  Terms:noexp]	  OR	  “gorilla	  
gorilla”[MeSH	  Terms]	  OR	  “pan	  paniscus”[MeSH	  Terms]	  OR	  “pan	  troglodytes”[MeSH	  Terms]	  OR	  “pongo	  
pygmaeus”[MeSH	  Terms])	  OR	  ((animals[tiab]	  OR	  animal[tiab]	  OR	  mice[Tiab]	  OR	  mus[Tiab]	  OR	  mouse[Tiab]	  OR	  
murine[Tiab]	  OR	  woodmouse[tiab]	  OR	  rats[Tiab]	  OR	  rat[Tiab]	  OR	  murinae[Tiab]	  OR	  muridae[Tiab]	  OR	  cottonrat[tiab]	  
OR	  cottonrats[tiab]	  OR	  hamster[tiab]	  OR	  hamsters[tiab]	  OR	  cricetinae[tiab]	  OR	  rodentia[Tiab]	  OR	  rodent[Tiab]	  OR	  
rodents[Tiab]	  OR	  pigs[Tiab]	  OR	  pig[Tiab]	  OR	  swine[tiab]	  OR	  swines[tiab]	  OR	  piglets[tiab]	  OR	  piglet[tiab]	  OR	  boar[tiab]	  
OR	  boars[tiab]	  OR	  “sus	  scrofa”[tiab]	  OR	  ferrets[tiab]	  OR	  ferret[tiab]	  OR	  ferrets[tiab]	  OR	  polecat[tiab]	  OR	  polecats[tiab]	  
OR	  “mustela	  putorius”[tiab]	  OR	  “guinea	  pigs”[Tiab]	  OR	  “guinea	  pig”[Tiab]	  OR	  cavia[Tiab]	  OR	  callithrix[Tiab]	  OR	  
marmoset[Tiab]	  OR	  marmosets[Tiab]	  OR	  cebuella[Tiab]	  OR	  hapale[Tiab]	  OR	  octodon[Tiab]	  OR	  chinchilla[Tiab]	  OR	  
chinchillas[Tiab]	  OR	  gerbillinae[Tiab]	  OR	  gerbil[Tiab]	  OR	  gerbils[Tiab]	  OR	  jird[Tiab]	  OR	  jirds[Tiab]	  OR	  merione[Tiab]	  OR	  




fly[Tiab]	  OR	  dipteral[Tiab]	  OR	  drosphila[Tiab]	  OR	  drosophilidae[Tiab]	  OR	  cats[Tiab]	  OR	  cat[Tiab]	  OR	  carus[Tiab]	  OR	  
felis[Tiab]	  OR	  nematoda[Tiab]	  OR	  nematode[Tiab]	  OR	  nematoda[Tiab]	  OR	  nematode[Tiab]	  OR	  nematodes[Tiab]	  OR	  
sipunculida[Tiab]	  OR	  dogs[Tiab]	  OR	  dog[Tiab]	  OR	  canine[Tiab]	  OR	  canines[Tiab]	  OR	  canis[Tiab]	  OR	  sheep[Tiab]	  OR	  
sheeps[Tiab]	  OR	  mouflon[Tiab]	  OR	  mouflons[Tiab]	  OR	  ovis[Tiab]	  OR	  goats[Tiab]	  OR	  goat[Tiab]	  OR	  goats[Tiab]	  OR	  
capra[Tiab]	  OR	  capras[Tiab]	  OR	  rupicapra[Tiab]	  OR	  rupicapra[Tiab]	  OR	  chamois[Tiab]	  OR	  haplorhini[Tiab]	  OR	  
monkey[Tiab]	  OR	  monkeys[Tiab]	  OR	  anthropoidea[Tiab]	  OR	  anthropoids[Tiab]	  OR	  saguinus[Tiab]	  OR	  tamarin[Tiab]	  OR	  
tamarins[Tiab]	  OR	  leontopithecus[Tiab]	  OR	  hominidae[Tiab]	  OR	  ape[Tiab]	  OR	  apes[Tiab]	  OR	  pan[Tiab]	  OR	  
paniscus[Tiab]	  OR	  “pan	  paniscus”[Tiab]	  OR	  bonobo[Tiab]	  OR	  bonobos[Tiab]	  OR	  troglodytes[Tiab]	  OR	  “pan	  
troglodytes”[Tiab]	  OR	  gibbon[Tiab]	  OR	  gibbons[Tiab]	  OR	  siamang[Tiab]	  OR	  siamangs[Tiab]	  OR	  nomascus[Tiab]	  OR	  
symphalangus[Tiab]	  OR	  chimpanzee[Tiab]	  OR	  chimpanzees[Tiab]	  OR	  prosimians[Tiab]	  OR	  “bush	  baby”[Tiab]	  OR	  
prosimian[Tiab]	  OR	  bush	  babies[Tiab]	  OR	  galagos[Tiab]	  OR	  galago[Tiab]	  OR	  pongidae[Tiab]	  OR	  gorilla[Tiab]	  OR	  
gorilla[Tiab]	  OR	  pongo[Tiab]	  OR	  pygmaeus[Tiab]	  OR	  “pongo	  pygmaeus”[Tiab]	  OR	  orangutans[Tiab]	  OR	  pygmaeus[Tiab]	  
OR	  lemur[Tiab]	  OR	  lemurs[Tiab]	  OR	  lemuridae[Tiab]	  OR	  horse[Tiab]	  OR	  horses[Tiab]	  OR	  pongo[Tiab]	  OR	  equus[Tiab]	  OR	  
cow[Tiab]	  OR	  calf[Tiab]	  OR	  bull[Tiab]	  OR	  chicken[Tiab]	  OR	  chickens[Tiab]	  OR	  gallus[Tiab]	  OR	  quail[Tiab]	  OR	  bird[Tiab]	  
OR	  birds[Tiab]	  OR	  quails[Tiab]	  OR	  poultry[Tiab]	  OR	  poultries[Tiab]	  OR	  fowl[Tiab]	  OR	  fowls[Tiab]	  OR	  reptile[Tiab]	  OR	  
reptilia[Tiab]	  OR	  reptiles[Tiab]	  OR	  snakes[Tiab]	  OR	  snake[Tiab]	  OR	  lizard[Tiab]	  OR	  lizards[Tiab]	  OR	  alligator[Tiab]	  OR	  
alligators[Tiab]	  OR	  crocodile[Tiab]	  OR	  crocodiles[Tiab]	  OR	  turtle[Tiab]	  OR	  turtles[Tiab]	  OR	  amphibian[Tiab]	  OR	  
amphibians[Tiab]	  OR	  amphibia[Tiab]	  OR	  frog[Tiab]	  OR	  frogs[Tiab]	  OR	  bombina[Tiab]	  OR	  salientia[Tiab]	  OR	  toad[Tiab]	  
OR	  toads[Tiab]	  OR	  “epidalea	  calamita”[Tiab]	  OR	  salamander[Tiab]	  OR	  salamanders[Tiab]	  OR	  eel[Tiab]	  OR	  eels[Tiab]	  OR	  
fish[Tiab]	  OR	  fishes[Tiab]	  OR	  pisces[Tiab]	  OR	  catfish[Tiab]	  OR	  catfishes[Tiab]	  OR	  siluriformes[Tiab]	  OR	  arius[Tiab]	  OR	  
heteropneustes[Tiab]	  OR	  sheatfish[Tiab]	  OR	  perch[Tiab]	  OR	  perches[Tiab]	  OR	  percidae[Tiab]	  OR	  perca[Tiab]	  OR	  
trout[Tiab]	  OR	  trouts[Tiab]	  OR	  char[Tiab]	  OR	  chars[Tiab]	  OR	  salvelinus[Tiab]	  OR	  “fathead	  minnow”[Tiab]	  OR	  
minnow[Tiab]	  OR	  cyprinidae[Tiab]	  OR	  carps[Tiab]	  OR	  carp[Tiab]	  OR	  zebrafish[Tiab]	  OR	  zebrafishes[Tiab]	  OR	  
goldfish[Tiab]	  OR	  goldfishes[Tiab]	  OR	  guppy[Tiab]	  OR	  guppies[Tiab]	  OR	  chub[Tiab]	  OR	  chubs[Tiab]	  OR	  tinca[Tiab]	  OR	  
barbels[Tiab]	  OR	  barbus[Tiab]	  OR	  pimephales[Tiab]	  OR	  promelas[Tiab]	  OR	  “poecilia	  reticulata”[Tiab]	  OR	  mullet[Tiab]	  
OR	  mullets[Tiab]	  OR	  eel[Tiab]	  OR	  eels[Tiab]	  OR	  seahorse[Tiab]	  OR	  seahorses[Tiab]	  OR	  mugil	  curema[Tiab]	  OR	  atlantic	  
cod[Tiab]	  OR	  shark[Tiab]	  OR	  sharks[Tiab]	  OR	  catshark[Tiab]	  OR	  anguilla[Tiab]	  OR	  salmonid[Tiab]	  OR	  salmonids[Tiab]	  OR	  
whitefish[Tiab]	  OR	  whitefishes[Tiab]	  OR	  salmon[Tiab]	  OR	  salmons[Tiab]	  OR	  sole[Tiab]	  OR	  solea[Tiab]	  OR	  “sea	  
lamprey”[Tiab]	  OR	  lamprey[Tiab]	  OR	  lampreys[Tiab]	  OR	  pumpkinseed[Tiab]	  OR	  sunfish[Tiab]	  OR	  sunfishes[Tiab]	  OR	  
tilapia[Tiab]	  OR	  tilapias[Tiab]	  OR	  turbot[Tiab]	  OR	  turbots[Tiab]	  OR	  flatfish[Tiab]	  OR	  flatfishes[Tiab]	  OR	  sciuridae[Tiab]	  
OR	  squirrel[Tiab]	  OR	  squirrels[Tiab]	  OR	  chipmunk[Tiab]	  OR	  chipmunks[Tiab]	  OR	  suslik[Tiab]	  OR	  susliks[Tiab]	  OR	  
vole[Tiab]	  OR	  voles[Tiab]	  OR	  lemming[Tiab]	  OR	  lemmings[Tiab]	  OR	  muskrat[Tiab]	  OR	  muskrats[Tiab]	  OR	  lemmus[Tiab]	  
OR	  otter[Tiab]	  OR	  otters[Tiab]	  OR	  marten[Tiab]	  OR	  martens[Tiab]	  OR	  martes[Tiab]	  OR	  weasel[Tiab]	  OR	  badger[Tiab]	  OR	  
ermine[Tiab]	  OR	  mink[Tiab]	  OR	  sable[Tiab]	  OR	  sables[Tiab]	  OR	  badgers[Tiab]	  OR	  gulo[Tiab]	  OR	  gulos[Tiab]	  OR	  
wolverine[Tiab]	  OR	  wolverines[Tiab]	  OR	  minks[Tiab]	  OR	  mustela[Tiab]	  OR	  llama[Tiab]	  OR	  llamas[Tiab]	  OR	  alpaca[Tiab]	  
OR	  alpacas[Tiab]	  OR	  camelid[Tiab]	  OR	  camelids[Tiab]	  OR	  guanaco[Tiab]	  OR	  guanacos[Tiab]	  OR	  chiroptera[Tiab]	  OR	  
chiropteras[Tiab]	  OR	  bat[Tiab]	  OR	  bats[Tiab]	  OR	  fox[Tiab]	  OR	  foxes[Tiab]	  OR	  iguana[Tiab]	  OR	  iguanas[Tiab]	  OR	  xenopus	  
laevis[Tiab]	  OR	  parakeet[Tiab]	  OR	  parakeets[Tiab]	  OR	  parrot[Tiab]	  OR	  parrots[Tiab]	  OR	  donkey[Tiab]	  OR	  donkeys[Tiab]	  
OR	  mule[Tiab]	  OR	  mules[Tiab]	  OR	  zebra[Tiab]	  OR	  zebras[Tiab]	  OR	  shrew[Tiab]	  OR	  shrews[Tiab]	  OR	  bison[Tiab]	  OR	  
bisons[Tiab]	  OR	  buffalo[Tiab]	  OR	  buffaloes[Tiab]	  OR	  deer[Tiab]	  OR	  deers[Tiab]	  OR	  bear[Tiab]	  OR	  bears[Tiab]	  OR	  
panda[Tiab]	  OR	  pandas[Tiab]	  OR	  “wild	  hog”[Tiab]	  OR	  “wild	  boar”[Tiab]	  OR	  fitchew[Tiab]	  OR	  fitch[Tiab]	  OR	  beaver[Tiab]	  
OR	  beavers[Tiab]	  OR	  jerboa[Tiab]	  OR	  jerboas[Tiab]	  OR	  capybara[Tiab]	  OR	  capybaras[Tiab]	  OR	  minks[Tiab])	  NOT	  
medline[sb])	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exp	  animal	  experiment/	  OR	  exp	  animal	  model/	  OR	  exp	  experimental	  animal/	  OR	  exp	  transgenic	  animal/	  OR	  exp	  male	  
animal/	  OR	  exp	  female	  animal/	  OR	  exp	  juvenile	  animal/	  OR	  animal/	  OR	  chordata/	  OR	  vertebrate/	  OR	  tetrapod/	  OR	  exp	  
fish/	  OR	  amniote/	  OR	  exp	  amphibia/	  OR	  mammal/	  OR	  exp	  reptile/	  OR	  exp	  sauropsid/	  OR	  therian/OR	  exp	  
monotremate/	  OR	  placental	  mammals/	  OR	  exp	  marsupial/	  OR	  Euarchontoglires/	  OR	  exp	  Afrotheria/	  OR	  exp	  
Boreoeutheria/	  OR	  exp	  Laurasiatheria/	  OR	  exp	  Xenarthra/	  OR	  primate/	  OR	  exp	  Dermoptera/	  OR	  exp	  Glires/	  OR	  exp	  
Scandentia/	  OR	  Haplorhini/	  OR	  exp	  prosimian/	  OR	  simian/	  OR	  exp	  tarsiiform/	  OR	  Catarrhini/	  OR	  exp	  Platyrrhini/	  OR	  
ape/	  OR	  exp	  Cercopithecidae/	  OR	  hominid/	  OR	  exp	  hylobatidae/	  OR	  exp	  chimpanzee/	  OR	  exp	  gorilla/	  OR	  exp	  orang	  
utan/	  OR	  (animal	  OR	  animals	  OR	  pisces	  OR	  fish	  OR	  fishes	  OR	  catfish	  OR	  catfishes	  OR	  sheatfish	  OR	  silurus	  OR	  arius	  OR	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heteropneustes	  OR	  clarias	  OR	  gariepinus	  OR	  fathead	  minnow	  OR	  fathead	  minnows	  OR	  pimephales	  OR	  promelas	  OR	  
cichlidae	  OR	  trout	  OR	  trouts	  OR	  char	  OR	  chars	  OR	  salvelinus	  OR	  salmo	  OR	  oncorhynchus	  OR	  guppy	  OR	  guppies	  OR	  
millionfish	  OR	  poecilia	  OR	  goldfish	  OR	  goldfishes	  OR	  carassius	  OR	  auratus	  OR	  mullet	  OR	  mullets	  OR	  mugil	  OR	  curema	  
OR	  shark	  OR	  sharks	  OR	  cod	  OR	  cods	  OR	  gadus	  OR	  morhua	  OR	  carp	  OR	  carps	  OR	  cyprinus	  OR	  carpio	  OR	  killifish	  OR	  eel	  
OR	  eels	  OR	  anguilla	  OR	  zander	  OR	  sander	  OR	  lucioperca	  OR	  stizostedion	  OR	  turbot	  OR	  turbots	  OR	  psetta	  OR	  flatfish	  OR	  
flatfishes	  OR	  plaice	  OR	  pleuronectes	  OR	  platessa	  OR	  tilapia	  OR	  tilapias	  OR	  oreochromis	  OR	  sarotherodon	  OR	  common	  
sole	  OR	  dover	  sole	  OR	  solea	  OR	  zebrafish	  OR	  zebrafishes	  OR	  danio	  OR	  rerio	  OR	  seabass	  OR	  dicentrarchus	  OR	  labrax	  OR	  
morone	  OR	  lamprey	  OR	  lampreys	  OR	  petromyzon	  OR	  pumpkinseed	  OR	  pumpkinseeds	  OR	  lepomis	  OR	  gibbosus	  OR	  
herring	  OR	  clupea	  OR	  harengus	  OR	  amphibia	  OR	  amphibian	  OR	  amphibians	  OR	  anura	  OR	  salientia	  OR	  frog	  OR	  frogs	  OR	  
rana	  OR	  toad	  OR	  toads	  OR	  bufo	  OR	  xenopus	  OR	  laevis	  OR	  bombina	  OR	  epidalea	  OR	  calamita	  OR	  salamander	  OR	  
salamanders	  OR	  newt	  OR	  newts	  OR	  triturus	  OR	  reptilia	  OR	  reptile	  OR	  reptiles	  OR	  bearded	  dragon	  OR	  pogona	  OR	  
vitticeps	  OR	  iguana	  OR	  iguanas	  OR	  lizard	  OR	  lizards	  OR	  anguis	  fragilis	  OR	  turtle	  OR	  turtles	  OR	  snakes	  OR	  snake	  OR	  aves	  
OR	  bird	  OR	  birds	  OR	  quail	  OR	  quails	  OR	  coturnix	  OR	  bobwhite	  OR	  colinus	  OR	  virginianus	  OR	  poultry	  OR	  poultries	  OR	  
fowl	  OR	  fowls	  OR	  chicken	  OR	  chickens	  OR	  gallus	  OR	  zebra	  finch	  OR	  taeniopygia	  OR	  guttata	  OR	  canary	  OR	  canaries	  OR	  
serinus	  OR	  canaria	  OR	  parakeet	  OR	  parakeets	  OR	  grasskeet	  OR	  parrot	  OR	  parrots	  OR	  psittacine	  OR	  psittacines	  OR	  
shelduck	  OR	  tadorna	  OR	  goose	  OR	  geese	  OR	  branta	  OR	  leucopsis	  OR	  woodlark	  OR	  lullula	  OR	  flycatcher	  OR	  ficedula	  OR	  
hypoleuca	  OR	  dove	  OR	  doves	  OR	  geopelia	  OR	  cuneata	  OR	  duck	  OR	  ducks	  OR	  greylag	  OR	  graylag	  OR	  anser	  OR	  harrier	  OR	  
circus	  pygargus	  OR	  red	  knot	  OR	  great	  knot	  OR	  calidris	  OR	  canutus	  OR	  godwit	  OR	  limosa	  OR	  lapponica	  OR	  meleagris	  OR	  
gallopavo	  OR	  jackdaw	  OR	  corvus	  OR	  monedula	  OR	  ruff	  OR	  philomachus	  OR	  pugnax	  OR	  lapwing	  OR	  peewit	  OR	  plover	  
OR	  vanellus	  OR	  swan	  OR	  cygnus	  OR	  columbianus	  OR	  bewickii	  OR	  gull	  OR	  chroicocephalus	  OR	  ridibundus	  OR	  albifrons	  
OR	  great	  tit	  OR	  parus	  OR	  aythya	  OR	  fuligula	  OR	  streptopelia	  OR	  risoria	  OR	  spoonbill	  OR	  platalea	  OR	  leucorodia	  OR	  
blackbird	  OR	  turdus	  OR	  merula	  OR	  blue	  tit	  OR	  cyanistes	  OR	  pigeon	  OR	  pigeons	  OR	  columba	  OR	  pintail	  OR	  anas	  OR	  
starling	  OR	  sturnus	  OR	  owl	  OR	  athene	  noctua	  OR	  pochard	  OR	  ferina	  OR	  cockatiel	  OR	  nymphicus	  OR	  hollandicus	  OR	  
skylark	  OR	  alauda	  OR	  tern	  OR	  sterna	  OR	  teal	  OR	  crecca	  OR	  oystercatcher	  OR	  haematopus	  OR	  ostralegus	  OR	  shrew	  OR	  
shrews	  OR	  sorex	  OR	  araneus	  OR	  crocidura	  OR	  russula	  OR	  european	  mole	  OR	  talpa	  OR	  chiroptera	  OR	  bat	  OR	  bats	  OR	  
eptesicus	  OR	  serotinus	  OR	  myotis	  OR	  dasycneme	  OR	  daubentonii	  OR	  pipistrelle	  OR	  pipistrellus	  OR	  cat	  OR	  cats	  OR	  felis	  
OR	  catus	  OR	  feline	  OR	  dog	  OR	  dogs	  OR	  canis	  OR	  canine	  OR	  canines	  OR	  otter	  OR	  otters	  OR	  lutra	  OR	  badger	  OR	  badgers	  
OR	  meles	  OR	  fitchew	  OR	  fitch	  OR	  foumart	  or	  foulmart	  OR	  ferrets	  OR	  ferret	  OR	  polecat	  OR	  polecats	  OR	  mustela	  OR	  
putorius	  OR	  weasel	  OR	  weasels	  OR	  fox	  OR	  foxes	  OR	  vulpes	  OR	  common	  seal	  OR	  phoca	  OR	  vitulina	  OR	  grey	  seal	  OR	  
halichoerus	  OR	  horse	  OR	  horses	  OR	  equus	  OR	  equine	  OR	  equidae	  OR	  donkey	  OR	  donkeys	  OR	  mule	  OR	  mules	  OR	  pig	  OR	  
pigs	  OR	  swine	  OR	  swines	  OR	  hog	  OR	  hogs	  OR	  boar	  OR	  boars	  OR	  porcine	  OR	  piglet	  OR	  piglets	  OR	  sus	  OR	  scrofa	  OR	  llama	  
OR	  llamas	  OR	  lama	  OR	  glama	  OR	  deer	  OR	  deers	  OR	  cervus	  OR	  elaphus	  OR	  cow	  OR	  cows	  OR	  bos	  taurus	  OR	  bos	  indicus	  
OR	  bovine	  OR	  bull	  OR	  bulls	  OR	  cattle	  OR	  bison	  OR	  bisons	  OR	  sheep	  OR	  sheeps	  OR	  ovis	  aries	  OR	  ovine	  OR	  lamb	  OR	  
lambs	  OR	  mouflon	  OR	  mouflons	  OR	  goat	  OR	  goats	  OR	  capra	  OR	  caprine	  OR	  chamois	  OR	  rupicapra	  OR	  leporidae	  OR	  
lagomorpha	  OR	  lagomorph	  OR	  rabbit	  OR	  rabbits	  OR	  oryctolagus	  OR	  cuniculus	  OR	  laprine	  OR	  hares	  OR	  lepus	  OR	  
rodentia	  OR	  rodent	  OR	  rodents	  OR	  murinae	  OR	  mouse	  OR	  mice	  OR	  mus	  OR	  musculus	  OR	  murine	  OR	  woodmouse	  OR	  
apodemus	  OR	  rat	  OR	  rats	  OR	  rattus	  OR	  norvegicus	  OR	  guinea	  pig	  OR	  guinea	  pigs	  OR	  cavia	  OR	  porcellus	  OR	  hamster	  OR	  
hamsters	  OR	  mesocricetus	  OR	  cricetulus	  OR	  cricetus	  OR	  gerbil	  OR	  gerbils	  OR	  jird	  OR	  jirds	  OR	  meriones	  OR	  unguiculatus	  
OR	  jerboa	  OR	  jerboas	  OR	  jaculus	  OR	  chinchilla	  OR	  chinchillas	  OR	  beaver	  OR	  beavers	  OR	  castor	  fiber	  OR	  castor	  
canadensis	  OR	  sciuridae	  OR	  squirrel	  OR	  squirrels	  OR	  sciurus	  OR	  chipmunk	  OR	  chipmunks	  OR	  marmot	  OR	  marmots	  OR	  
marmota	  OR	  suslik	  OR	  susliks	  OR	  spermophilus	  OR	  cynomys	  OR	  cottonrat	  OR	  cottonrats	  OR	  sigmodon	  OR	  vole	  OR	  voles	  
OR	  microtus	  OR	  myodes	  OR	  glareolus	  OR	  primate	  OR	  primates	  OR	  prosimian	  OR	  prosimians	  OR	  lemur	  OR	  lemurs	  OR	  
lemuridae	  OR	  loris	  OR	  bush	  baby	  OR	  bush	  babies	  OR	  bushbaby	  OR	  bushbabies	  OR	  galago	  OR	  galagos	  OR	  anthropoidea	  
OR	  anthropoids	  OR	  simian	  OR	  simians	  OR	  monkey	  OR	  monkeys	  OR	  marmoset	  OR	  marmosets	  OR	  callithrix	  OR	  cebuella	  
OR	  tamarin	  OR	  tamarins	  OR	  saguinus	  OR	  leontopithecus	  OR	  squirrel	  monkey	  OR	  squirrel	  monkeys	  OR	  saimiri	  OR	  night	  
monkey	  OR	  night	  monkeys	  OR	  owl	  monkey	  OR	  owl	  monkeys	  OR	  douroucoulis	  OR	  aotus	  OR	  spider	  monkey	  OR	  spider	  
monkeys	  OR	  ateles	  OR	  baboon	  OR	  baboons	  OR	  papio	  OR	  rhesus	  monkey	  OR	  macaque	  OR	  macaca	  OR	  mulatta	  OR	  
cynomolgus	  OR	  fascicularis	  OR	  green	  monkey	  OR	  green	  monkeys	  OR	  chlorocebus	  OR	  vervet	  OR	  vervets	  OR	  pygerythrus	  
OR	  hominoidea	  OR	  ape	  OR	  apes	  OR	  hylobatidae	  OR	  gibbon	  OR	  gibbons	  OR	  siamang	  OR	  siamangs	  OR	  nomascus	  OR	  
symphalangus	  OR	  hominidae	  OR	  orangutan	  OR	  orangutans	  OR	  pongo	  OR	  chimpanzee	  OR	  chimpanzees	  OR	  pan	  











Species/Strain    Age   
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outcome variables    Number of Defects  Mean  SD 
Histomorphometrical bone area 
(BA%) 
Test      
control      
Micro‐CT bone volume (%BV) 
Test      
control      
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A. Histomorphometrical Bone Area (BA%) - Subgroups
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B. Micro-CT Bone Volume (BV%) - Overall
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CHAPTER FOUR
Impact of single or combined drug therapy 
on bone regeneration in healthy and 
osteoporotic rats 
Marwa Y. Shaheen, Amani M. Basudan, Abdurahman A. 
Niazy, Jeroen J.J.P. van den Beucken, John A. Jansen, 
Hamdan S. Alghamdi





Complications in bone regeneration in patients with systemic impaired 
bone metabolism (e.g. osteoporosis) represent a rapidly increasing 
clinical challenge. Alendronate and simvastatin are drugs commonly 
used to promote bone metabolism in osteoporotic conditions. The aim 
of this study was to evaluate initial bone regeneration within osseous 
defects grafted with beta-tricalcium phosphate (β-TCP) in adjunction 
with systemic co-administrations of alendronate and simvastatin (i.e. 
daily subcutaneous injection for 3 weeks) in healthy and osteoporotic 
rats. Eighty Wistar female rats were ovariectomized (OVX; n=40) or 
sham operated (n=40). Six weeks later, osseous defects (a 3-mm 
critical-sized defect) were created in the left femoral condyles, and 
then grafted with β-TCP. From the day following graft installation, OVX 
and sham animals received for 3 weeks a daily subcutaneous injection 
of alendronate (50 µg/kg of body weight), simvastatin (5 mg/kg of 
bodyweight), alone or in combination. A control group was included, 
which received subcutaneous saline administration. At the end of the 
3 weeks, rats were euthanized and specimens (femoral condyles) were 
retrieved for histological evaluation and histomorphometric 
measurements, i.e. bone area (BA%) and remaining bone graft 
(RBG%). In osteoporotic rats, 3-weeks of daily subcutaneous injection 
of combined therapy (alendronate plus simvastatin) led to a significant 
(p<0.05) increase in BA% and a significant decrease in RBG% 
compared to healthy controls in osseous defects grafted with β-TCP 
(BA%: 28.6 ±12.0 vs. 18.2 ±7.6, RBG% 61.3 ±11.1 vs. 70.7 ±7.3). No 
significant differences in BA% and RBG% were found in the OVX rats 
for single treatments. Further, healthy controls showed similar BA% 
and RBG% upon single or combined therapy compared to non-treated 
control rats. Daily co-injections (for 3 weeks) of alendronate plus 
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simvastatin results in a significant enhancement of bone regeneration 
within osseous defects grafted with β-TCP in osteoporotic rats. Despite 
the expected effects on osteoporotic bone, our study did not confirm 
the hypothesized benefit of alendronate and simvastatin on bone 
regeneration in osseous defects in healthy conditions. The efficacy of 
the combination drug therapy on bone regeneration demands further 
investigation to elucidate molecular and cellular aspects underlying 
this therapy.






Bone grafting in dentistry is used to replace missing alveolar bone due 
to tooth extraction, chronic periodontal disease, or dental trauma [1].
The bone graft, as installed into the bone defect, provides a scaffold, 
which has to stimulate and contribute to bone formation [2].The 
rationale for bone grafting is based on the biological principles of 
osteogenesis, osteoconduction and osteoinduction [3]. Bone grafts 
can be categorized either as autografts (obtained from the same 
patient), allografts (obtained from human donors), xenografts 
(obtained from non-human sources) or alloplastic materials (synthetic 
bone substitutes) [4]. Each type of bone graft material has inherent 
advantages and disadvantages. Autograft bone is considered as the 
gold standard, but has several clinical limitations, like limited 
availability and donor-site morbidity [5-7]. While allograft bone has 
been considered as an alternative, it is associated with the risk of 
disease transmission [8]. Therefore, synthetic bone graft substitutes 
have been developed as off-the-shelf available alternatives.
Over the last decade, a wide variety of synthetic bone graft materials 
have become available. The most common ones are composed of 
calcium phosphate (CaP) ceramics [9, 10] CaP-based bone substitutes 
have garnered considerable interest due to their similarity in chemical 
composition with that of natural bone mineral [11, 12]. One of the 
most frequently used calcium phosphate ceramics for bone grafting in 
dentistry is beta-tricalcium phosphate (β-TCP) as it promotes healing 
and shows great osteoconductive potential for alveolar bone [13,14].
Despite the reported beneficial effect of β-TCP as a bone regenerative 
material, it has to be noticed that most of the published data are 
dealing with studies performed in healthy animals and humans. 
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However, bone healing can be impaired due to systemic diseases, such 
as osteoporosis and diabetes, which affect the bone metabolism and 
turnover [15, 16]. Consequently, such systemic diseases can hamper 
the regenerative effect of a bone graft material. For local challenging 
conditions with healthy bone, such as large osseous defects, 
osteostimulative factors can be used in combination with β-TCP bone 
grafting to promote bone healing [14, 16-18]. In addition, in the 
presence of compromised bone metabolism, such as osteoporosis, the 
combination of β-TCP bone grafting with anti-osteoporotic drugs 
improves the quality and quantity of newly formed bone in osseous 
defects [16]. Hence, anti-osteoporotic drugs are being suggested as 
adjunctive treatment modality to manage challenged bone defects. 
Two different classes of anti-osteoporotic drugs are clinically used, i.e. 
the anti-resorptive drugs such as bisphosphonates (e.g. alendronate) 
and the anabolic drugs like simvastatin [19]. While the anti-resorptive 
drugs reduce further bone loss by inhibiting osteoclasts, the anabolic 
drugs increase osteoblastic activity, hasten callus formation and bone 
healing in response to injury [18-21].
In osteoporotic research, a growing number of preclinical and clinical 
studies have introduced the concept of the co-administration of two 
drugs (i.e. combination treatment) to overcome the limitations of 
mono-therapy in treating osteoporotic bone, as the administration of 
alendronate alone is not always effective in treating bone damage 
and reversing osteoporosis severity [22]. Therefore, co-administration 
of alendronate and simvastatin is commonly applied due to their 
distinctly different mechanisms of action. Indeed, the systemic 
administration of an anabolic drug was shown to have a potential 
effect related to the complementary mechanism by inducing bone 




slowed down the pathogenesis of osteoclastic cells hyperactivity [18].
In dental clinics, osteoporotic patients receiving systemic anti-
osteoporotic drugs, either single or combined, need treatment of 
dento-alveolar and craniofacial bone defects using a bone substituting 
material. For such a clinical scenario, we questioned whether the use 
of systemic anti-osteoporotic drugs can favor bone regeneration. 
Despite the beneficial effect of different anti-osteoporotic drugs on 
bone metabolism [18, 20, 23-25], the effect of the systemic co-
administration of alendronate and simvastatin on bone regeneration 
related to β-TCP granules in osteoporotic and healthy bone has not 
been investigated, yet.
In our study, we utilized the well-established femoral condyle model in 
healthy and osteoporotic rats. This animal model has been previously 
characterized by our research group to study bone regeneration 
related to biomaterials [26]. Also, we have shown in our past study 
[27] that untreated 3-mm defects did not heal without intervention 
making the rat femoral condyle model a well-established and 
standardized defect model for evaluating bone regeneration in 
healthy and osteoporotic bone. 
The aim of this study was to evaluate bone regeneration within 
osseous defects grafted with β-TCP in adjunction with single or 
combined therapy using alendronate and simvastatin (i.e. daily 
subcutaneous injection for 3 weeks) in healthy and osteoporotic 
animal models.
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The present study was approved by the Animal Ethics Committee of 
King Saud University, College of Dentistry, Saudi Arabia (Approval No. 
4/67/389683). A total of 80 skeletally mature female Wistar rats (12 
weeks age and weight of ~250g) were included in this study. Forty of 
these rats were ovariectomized (OVX) to induce osteoporosis and the 
remaining 40 rats were subjected to sham surgery (SHAM)[26]. The 
animals were housed in standardized rat cages (4-5 animals per cage) 
maintained in a laboratory environment with controlled temperature 
(22-24˚C) and humidity (45% – 55%) and 12-hourly light and dark 
cycles. All the animals had ad libitum access to a standard rat chow 
diet and water.
Surgical procedures and bone grafting
Six weeks after OVX/SHAM operations, the bone grafting procedures 
were performed under general anesthesia and sterile aseptic 
conditions (Figure 1). In brief, the rats were anaesthetized 
intramuscularly using xylazine (Chanazine, Chanelle Pharmaceutical, 
Dublin, Ireland) 5mg/kg body weight and ketamine hydrochloride 
(Ketamine, Pharmazeutische Präparate, Giessen, Germany) 30mg/kg 
body weight. Subsequently, each animal was immobilized in a supine 
position with the left knee joint in a maximally flexed position. The left 
leg was shaved, washed and disinfected with 10% Povidone-iodine 
solution. A mid-line longitudinal parapatellar incision was made over 
the left knee to expose the joint capsule. The entire knee joint was 
exposed after incising the capsule longitudinally and retracting the 
patellar ligament laterally. This maneuver was facilitated by a slight 




in diameter and 3mm in depth, was created in the femoral 
intercondylar notch, using a surgical bur in a rotary hand piece 
(Elcomed 100, W&H Dental werk Burmoos, Austria) at a speed of 800 
rpm and continuous saline irrigation for cooling and debridement. The 
bone defects in all animals were grafted with synthetic β-TCP granules 
(β-TCP, 150-500um, Kasios TCP, Dental HP, France). Following bone 
graft placement, the overlying soft tissue and skin were closed in 
layers using resorbable VICRYL™ (4-0) polyglactin 910 Sutures (Ethicon, 
Johnson & Johnson, New Brunswick, New Jersey, USA).
Figure 1: Picture of the surgical procedure: the femoral condyle exposed, bone defect 
(3mm in diameter and 3mm in depth) created and filled with β-TCP.
Administration of anti-osteoporotic drugs
From the day following synthetic graft installation, OVX and SHAM 
animals received subcutaneous administration of alendronate (50 µg/
kg of body weight) and simvastatin (5 mg/kg of bodyweight), alone or 
in combination, daily for 3 weeks, as previously [28] shown to promote 
bone formation in rats. The experimental groups and timetable are 
depicted in Figure 2:
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• Alendronate (ALN) monotherapy (50 µg/kg) (Fosamax®, Merck 
Sharp & Dohme Ltd, United Kingdom) was used for 20 animals (10 
OVX, 10 SHAM).
• Simvastatin (SIM) monotherapy (5 mg/kg) (Zocor®, Merck Sharp & 
Dohme B.V, Netherlands) was used for 20 animals (10 OVX, 10 
SHAM).
• Combined therapy (ALN+SIM) was used for 20 animals (10 OVX, 10 
SHAM).
• Subcutaneous saline administration (10 ml) was used for 20 
animals (10 OVX, 10 SHAM) as a control.
Figure 2: Flow chart describing the study design, test groups and different anti-
osteoporotic drug treatment protocols.
Sample retrieval, preparation, and analyses
Three weeks post-implantation, all rats were euthanized by CO2-
suffocation.  The femoral condyles were carefully dissected and 
adhering soft tissues were removed. The specimens were then 
immediately fixed in neutral buffered formaldehyde for 48 hours. After 
fixation, specimens were stored in 70% ethanol and subsequently 




Histological preparation and evaluation
pMMA sections: A part of the specimens (n = 5 specimens per group 
and per drug administration protocol) were embedded after 
dehydration in a graded series of alcohol in poly(methyl methacrylate) 
(pMMA) resin. After polymerization, thin non-decalcified serial 
transversal sections (perpendicular to long axis of grafted bone 
substitutes) were cut at a thickness of ~10 μm using a sawing 
microtome (Leica SP-1600, Leica Microsystems Nussloch GmbH, 
Heidelberger, Germany), based on the technique described previously 
[29]. The non-decalcified sections were then stained with methylene 
blue and basic fuchsin.
Paraffin sections: The remaining specimens (n = 5 specimens per 
group and per drug administration protocol) were decalcified in EDTA 
solution following dehydration using ascending ethanol concentration 
(70 to 100%). The decalcified specimens were then embedded in 
paraffin and sectioned with a thickness of ~5μm transversely 
(perpendicular to long axis of grafted bone substitutes) using a 
microtome (RM 2156, Leica Microsystems, Nussloch, Germany). Serial 
histological sections were mounted on glass slides and stained with 
hematoxylin and eosin (H&E) stain, elastin van Gieson (EVG) stain, 
tartrate–resistant acid phosphatase (TRAP) stain, and osteocalcin 
(OSC) stain, respectively.
Histomorphometrical examination
Histological images of all the stained sections were obtained and 
recorded using Aperio microscope (Aperio ImageScope, Leica 
Biosystems, USA). The digital images were acquired at x40 
magnification to investigate the structural appearance of the bone 
tissue.
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The pMMA sections were assigned for additional histomorphometric 
analysis. A 3mm diameter circular shape was superimposed onto the 
bone defect area, to be defined as the region of interest (ROI). 
Quantitative measurements were performed to assess the percentage 
of new bone area (BA%) and remaining bone graft (RBG%) using 
ImageJ software (Version 1.4, National Institute of Health, Bethesda, 
MD, USA).
Statistical analysis
Descriptive statistics including mean values and standard deviations 
were calculated for BA% and RBG%. GraphPad InStat® statistical 
software (GraphPad, San Diego California USA) was used for analyzing 
statistical differences between the study groups. Significant 
differences between the groups were determined using analysis of 
variance (ANOVA). Tukey-Kramer (Multiple Comparisons) post-hoc test 
was applied for comparison of the groups based on different 




Four animals died during the surgical grafting procedure due to 
anaesthesia complication (two OVX: ALN and combined, two SHAM: 
ALN and saline). The remaining study animals showed uneventful 
post-operative healing and stayed healthy during the entire 





Descriptive histology of osseous defect healing after 3 
weeks
Light microscopical examination of the histological sections of the 
whole femoral condyle at low magnification confirmed the induction 
of osteoporosis, as indicated by the decreased overall amount of the 
bone trabeculae and the increase in intertrabecular space for the rats 
receiving saline administration after OVX versus SHAM surgery (Figure 
3).
Three weeks postoperatively, the light microscopical examination of 
the pMMA sections showed similar histological details (Figure 4). In 
the sections, the edge of the defect could still be recognized. All pMMA 
sections revealed the presence of β-TCP particles surrounded by new 
bone tissue for all drug treatment protocols. Bone formation at the 
edges of the defect area was somewhat more pronounced than in the 
center of the defect. The newly formed bone was in close contact with 
the β-TCP particles. Administration of combined drug therapy seemed 
to result in somewhat more new bone formation in the center of the 
defects compared with monotherapy drug and saline administration 
(Figure 5). The newly formed bone was present, characterized as 
woven bone in a disorganized manner and in between the bone 
trabeculae bone marrow-like tissue (Figure 5). Evident degradation of 
the grafted β-TCP bone substitute was not observed in any defect, 
irrespective of the group and treatment protocol. Nevertheless, in 
areas were no bone was formed on the β-TCP particles, osteoclast-like 
cells were present in contact with the particle surface (Figure 4). In 
these areas, the β-TCP surface had a ruffled appearance.
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Analysis of the paraffin sections resulted in the same observations as 
for the pMMA sections. Representative images of paraffin sections of 
the combined therapy group in osteoporotic animals are depicted in 
(Figure 6). Hematoxylin-eosin (H&E) and EVG staining confirmed that 
bone formation was more enhanced at the edges of the defects. In 
the defect, β-TCP particles were present with in between bone. The 
new-formed bone was not mature and was characterized by the 
presence of osteoid and elastin fibers in the center of the defect. Bone 
marrow-like tissue could be observed between the particles and new 
bone, which was characterized by the presence of fat cells and blood 
vessels. TRAP staining indicated the abundant presence of osteoclast-
like cells surrounding the β-TCP particles (Figure 7). The osteoclast-like 
cells appeared to be in close contact with the surface of the β-TCP 
particles. Finally, osteocalcin staining confirmed that bone formation 
had proceeded into the center of the defects, as characterized by the 
diffuse brown staining of the newly formed bone matrix.
Histomorphometric evaluation of bone graft healing after 
3 weeks
As shown in Table 1 and Figure 8, mean BA% was significantly higher 
(p<0.05) in osteoporotic animals receiving combined treatment (28.6 
±12.0), in comparison to saline treated osteoporotic animals (18.2 
±7.6). Similarly, the mean RBG% (Figure 9) was significantly lower 
(p<0.05) in osteoporotic animals treated with alendronate and 
simvastatin (61.3 ±11.1) compared to those receiving saline only (70.7 
±7.3).
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In contrast, as depicted in Table 1 and Figure 8, no statistically 
differences existed in BA% between the various treatment groups in 
the healthy animals.  Further, similar mean values for RBG% (Table 1 
and Figure 9) were observed between the different treatment 
protocols in healthy animals. 







BA % RBG % BA % RBG %
Alendronate 26 ±9.6 62.8 ±9.3 18.4 ±12 70.7 ±11.1
Simvastatin 22.2 ±9.3 67.1 ±9.3 19.4 ±11.3 69.1 ±11.5
Combined 28.6 ±12.0* 61.3 ±11.1* 22.8 ±10.2 66.6 ±10.2
Saline 18.2 ±7.6 70.7 ±7.3 18 ±8.5 71.1 ±8.4
*P<0.05 between combined treatment and Saline in Osteoporotic Condition for BA % and RBG %
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Figure 7: Higher magnification from the center of defect related to the combined 
therapy group in the osteoporotic animals for, A, H&E, B, EVG, C, TRAP, and, D, 
osteocalcin sections. It all showed island of osteoid (ost), beta-tricalcium phosphate 
(TCP) granules, osteoclasts (OC), and osteoblasts (OB). Black arrows pointed to blood 




Figure 8: Bar-chart shows the mean BA% as significantly higher (p<0.05) in 
osteoporotic animals receiving combined treatment in comparison to saline. There 
were no statistically significant differences in the mean values of BA% between 
treatment protocols in healthy animals.
Figure 9: Bar-chart shows the mean RBG% as significantly lower (p<0.05) in 
osteoporotic animals treated with combined therapy compared to saline. There were 
no statistically significant differences in the mean values of RBG% between treatment 
protocols in healthy animals.
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DIsCUssION
The present study aimed to evaluate bone regeneration within 
osseous defects grafted with beta-tricalcium phosphate (β-TCP) in 
adjunction with single or combined therapy using alendronate and 
simvastatin (i.e. daily subcutaneous injection for 3 weeks) in healthy 
and osteoporotic rats. The histological examination of the whole 
femoral condyle clearly indicated a reduction in trabecular bone and 
an increase in intertrabecular spaces for the OVX vs. SHAM rats 
receiving saline administration, which confirmed induction of 
osteoporosis. The percentage of new bone area (BA%) within osseous 
defects grafted with β-TCP was significantly higher in osteoporotic 
animals treated with the combination of alendronate and simvastatin. 
In addition, the degradation of the β-TCP granules was enhanced in 
osteoporotic animals treated with the combination of alendronate 
and simvastatin. No significant differences in BA% were found in the 
osteoporotic rats receiving single treatment. Despite the hypothesized 
effect on osteoporotic bone, our study did not confirm the possible 
benefit of alendronate and simvastatin on bone regeneration in 
osseous defects in healthy condition.
Bone regeneration in osseous defects may be reduced in compromised 
conditions, e.g. osteoporosis, which is known to have a deleterious 
effect on bone tissue and its mineral density [2, 17, 30-32]. This was 
evident from previous observations, in which the lowest amount of 
new bone formation was observed for ovariectomized animals, despite 
of the use of bone grafting [14, 17, 19, 26, 33]. The role of anti-
osteoporotic drugs in stimulating bone regeneration has garnered 





The majority of anti-osteoporotic drugs are either anti-resorptive 
agents or anabolic agents. Anti-resorptive agents enhance bone 
mineral density by reducing the remodeling space and increasing 
average bone age by inhibiting osteoclastic activity and lowering 
bone turnover [34, 35]. Bisphosphonates are the predominantly used 
anti-resorptive agents used in conditions ranging from osteoporosis, 
metastatic bone disease and bone tumors [36-38]. As one of the most 
potent bisphosphonates, alendronate has been reportedly used 
successfully to stimulate in vivo bone formation when used along with 
allografts [36-38]. Alendronate, one of the first-line drugs used to treat 
post-menopausal osteoporosis in women, can be administered orally 
or systemically [18, 39]. Data from animal studies have reported 
favorable osseous healing and bone regeneration with allografts and 
autografts, along with both systemic and local administration of 
alendronate [23, 25, 40].
In addition to anti-resorptive agents, anabolic agents such as statins 
have also been shown to enhance bone regeneration in in-vivo 
studies, both in healthy and osteoporotic models [20, 41-44]. Statins 
are a group of orally administered drugs used for lowering cholesterol 
levels in blood and they act by inhibiting the enzyme HMG-CoA 
reductase (3-hydroxy-3-methylglutaryl coenzyme-A reductase) [45]. 
This statins group includes multiple drugs, including atorvastatin, 
rosuvastatin, and simvastatin. Simvastatin has been reported to exert 
anabolic effects and is presumed to have an anti-resorptive action on 
bone [46, 47]. The above effects of simvastatin are mediated through 
its ability to stimulate osteoblasts and to upregulate locally the 
expression of bone morphogenic protein-2 (BMP-2), a potent growth 
factor capable of osteoinduction [41]. While the adjunctive action of 
simvastatin on bone regeneration has been reported based either on 
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local administration or oral intake [42, 48, 49] the present study 
utilized subcutaneous injection as the route of administration. This 
was done as administration of higher doses of simvastatin has been 
reported to stimulate inflammation [49].
Interestingly, subcutaneous administration of combined therapy 
(alendronate plus simvastatin) in adjunction with bone grafting 
resulted in a significant increase in bone formation (histomorphometric 
BA%) in osteoporotic conditions. These findings are in line with the 
data reported by Mohamed et al. [24], where a combination of 
alendronate and simvastatin resulted in greater effects in the 
ovariectomized rat models [24]. It should be noticed that in the study 
of Mohamed et al. drugs were administered orally, while it was given 
subcutaneously in the current study. This was done in order to 
optimize the dosage administered to the animals, which may not be 
possible through the oral route.
However, the effect of systemic administration of either alendronate 
or simvastatin on bone regeneration with β-TCP was similar based on 
the histological assessment of bone formation (BA%) compared to 
saline-treated animals. A definite explanation for this observation is 
difficult to provide. We assume that this lack of effect can be caused 
by two reasons: (1) in the current study, all rats were euthanized three 
weeks after creation and grafting of the bone defect. This implantation 
period is relatively short and it can be supposed that bone remodeling 
at the defect site is not completed yet. As a consequence, the full 
effect of the anti-osteoporotic drug treatment is perhaps still not 
achieved, and (2) the anti-osteoporotic drugs were administered by 
subcutaneous injection. In human patients, anti-osteoporotic drugs 




administration has shown being not inferior to intravenous 
administration [50]. Although the effect of subcutaneous 
administration of alendronate has been confirmed in the study of Giro 
et al. [26], we do not know whether indeed the same blood 
concentration is achieved.
Besides, our study did not show the supposed benefit of co-
administration of alendronate and simvastatin on bone regeneration 
in healthy animals. The absence of an additional benefit of the 
combined drugs therapy on healthy bone is consistent with a previous 
preclinical study [51]. We assume that the function of these anti-
osteoporotic drugs will be more potent in the presence of bone 
pathology due to dysfunction of bone cells. However, more 
understanding of the different mechanism of action of anti-
osteoporotic drugs is crucial to settle an appropriate design of 
prospective pre(clinical) studies to achieve enhanced therapeutic 
advantage on bone regeneration in healthy as well as osteoporotic 
conditions.
In contrast to our results, previous studies reported an additive effect 
of alendronate alone on new bone formation in adjunction with bone 
grafting, both in osteoporotic and healthy animal models [23, 25, 36, 
40, 43, 44, 52-56]. Comparing the present results with those previous 
studies is difficult considering multifactorial differences in terms of 
drug type, dosage, frequency and route of administration, nature of 
osseous defect and graft material, and healing period. Nevertheless, 
in light of the limitations of the current study, like the short 
implantation time and still low number of animals, our data warrant 
further investigation into the individual effects of anti-osteoporotic 
drugs in osseous defect healing along with bone substitute materials.
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A critical comment has to be made on the way the histological 
sections were made. All defects were histologically assessed on basis 
of cross-sectional prepared sections perpendicular on the long-axis of 
the defect. This enabled us to evaluate the bone healing process in the 
peripheral and central regions of the defect. Unfortunately, the 
specimens could not be sectioned in a longitudinal plane due to 
difficultly in the reproducible positioning the specimens during 
embedding and sectioning. This is related to small defect diameter as 
well as the fact that long bones are not perfectly cylindrical in shape. 
Therefore, transverse sections were made, which can be collected in a 
uniform manner. Also, this sectioning approach provides an optimal 
means for both observing the variability of the bone tissue healing. 
The second practical aspect to be considered in the histological 
assessment is to identify appropriate histological stains. In general, a 
staining protocol should provide consistent staining outcome that will 
enhance histological tissue discrimination of bone from non-osseous 
tissue and can be used for histomorphometric analysis. The protocol, 
as used for pMMA embedding, makes it possible to prepare light 
microscopical sections of hard tissue specimens of high quality for 
histomorphometric analysis. However, this approach limits the use of 
histological staining techniques to characterize specific cell and tissue 
structures. Consequently, we decided use MMA embedding to prepare 
a sufficient number of specimens to allow statistical analysis of the 
histomorphometric data. Further, a limited number of specimens was 
decalcified and embedded in paraffin to allow the use of various 





Finally, it has to be mentioned that histological and histomorphometric 
2D evaluations were used in the present study instead of 3D 
examination by micro-CT imaging [57]. Although micro-CT imaging 
affords unique capabilities for non-destructive examination of macro- 
and microstructures of bone tissues, it is difficult to track newly formed 
bone regeneration adjacent to the bone substitutes [57]. In the 
present study, the bone defects were filled with β-TCP granules, which 
have similar gray value scale as the bone tissue. Therefore, it is not 
possible to discriminate between the newly formed bone and the 
remnant β-TCP materials by using micro-CT imaging. Additionally, the 
main technical aspects related to the acquisition and processing of 
micro-CT images to obtain quantitative data on bone regeneration 
related to bone grafting have several subjective manipulations. Micro-
CT quantification is particularly based on measuring bone mineral 
density according to the level of grayscale, which can be adjusted 
subjectively by the operator/investigator. Therefore, this kind of 
analytic method can cause bias in evaluating bone regeneration 
related to biomaterials due to many error sources affecting the 
imaging quality, such as change in acquisition settings, resolution, the 
type of scanner, voxel density values, standardizing the X-ray tube 
settings, the field of view, and the slice thickness of CT scan [57]. 
Besides, the healing time in the present study was 3 weeks, in which 
we expected more unmatured (osteoid) type of bone around the 
remnant β-TCP materials. Therefore, it is possible that the amount of 
newly formed (osteoid) bone is underestimated by micro-CT 
examination, because new bone can have a lower degree of 
mineralization (i.e. bone density). In addition, the micro-CT imaging 
and processing does not produce sharp transitions between the 
grafted material and the surrounded tissues. In consequence, the 
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grafted materials appear to be covered by a thin layer of lower 
mineral density (artefact transitions voxels), which is erroneously 
identified as mineralized bone by several investigators [58].
CONCLUsION
Based on the results of the present study, daily subcutaneous 
injections of combined therapy (alendronate plus simvastatin) resulted 
in significantly increased new bone formation, as evidenced by the 
BA% within femoral condylar defects grafted with β-TCP, in 
osteoporotic rats after a three weeks healing period. Despite the 
hypothesized effect on osteoporotic bone, our study did not confirm a 
benefit of alendronate and simvastatin on bone regeneration in 
osseous defects in healthy condition. The efficacy of the combination 
drug therapy on bone regeneration demands further investigation to 
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The objective of this study was to evaluate the regeneration of bone 
defects created in the femoral condyle of osteoporotic rats, which 
were systemically treated via intravenous (IV) dosing regimens of 
zoledronic acid (ZA) and compared to non-treated controls. Twenty-
four female Wistar rats were ovariectomized (OVX). After confirming 
osteoporotic condition, bone defects were created in the left femoral 
condyle of all rats (one defect per rat). All defects were grafted with 
particulate inorganic cancellous bovine bone substitute. Rats were IV 
injected on a weekly basis with ZA (0.04 mg/kg body weight) according 
to the following dosing regimens: (1) Group ZA-Pre (n=6 rats) was 
injected with ZA starting four weeks before creation of the bone 
defect, (2) Group ZA-Post (n=6 rats) was injected with ZA immediately 
after bone defect preparation and continued until the end of 
experiment, and (3) Group ZA-Pre+Post (n=6 rats) received IV ZA 4 
weeks before creation of the bone defect and ZA administration was 
continued until the end of experiment. A control group (n=6 rats) was 
included in the study, which was injected with physiological saline 
solution (Group-Saline). At 6 weeks post-defect preparation, all 
animals were euthanized and the femoral condyle specimens were 
harvested for histomorphometric assessment. Bone area percentage 
(BA%) and remaining bone graft percentage (RBG%) were determined.
Statistical analysis of the BA% measurements using ANOVA and 
Dunnett’s post-hoc testing revealed that BA% for ZA-Pre (50.1% ± 
3.5%) and ZA-Post (49.2% ± 8.2%) treatment was significantly 
increased (p-value resp. 0.031 and 0.043) compared to Saline control 
(35.4% ± 5.4%). In contrast, ZA-Pre+Post (40.7% ± 16.0%) tretament 
showed a similar BA% compared to Saline control treatment (p=0.663). 
For RBG%, all experimental groups showed similar results ranging 
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from 36.3 to 47.1%. In conclusion our data indicate that pre- or post-
surgical systemic IV administration of ZA improves bone regeneration 
of bone defects grafted with inorganic cancellous bovine-bone 
particles in osteoporotic bone conditions. However, no favorable effect 
on bone repair was seen for continued pre+post-surgical ZA treatment.





Skeletal conditions such as osteoporosis, which further accentuate 
bone resorption and healing, are a major challenge for bone 
regenerative procedures. The physiological process of bone healing is 
more complex in situations associated with metabolic disorders 
compared to a healthy condition [1, 2]. Osteoporosis decreases both 
cortical and trabecular bone mineralization and is often diagnosed in 
postmenopausal women. It is characterized by decreased bone mass 
and strength, altered microstructure, and reduced regenerative 
capacity [3, 4]. Medication is prescribed for osteoporosis treatment to 
improve the bone health. The mostly prescribed drugs are 
bisphosphonates (BPs), which reduce bone turnover by inhibiting the 
activity of osteoclasts [5, 6], where they disrupt intracellular processes 
required for osteoclast functioning [7].
Although oral BPs are routinely prescribed for the treatment of 
osteoporosis, they are also associated with undesirable side effects as 
a result of long-term therapeutic usage. For example, over the last 
decade, development of Bisphosphonate Related Osteonecrosis of 
Jaws (BRONJ) has been reported as a complication of long-term use of 
BPs [8]. It is therefore recommended that any person undergoing BP 
therapy be advised about the risk of BRONJ following oral surgical 
procedures such as dental extractions and bone grafting [9]. Despite 
the risk of BP administration for the development of a jaw disease, 
studies have also shown that BPs (particularly alendronate) may 
reduce alveolar bone resorption following dental extraction and can 
promote bone regeneration [6, 10, 11]. In view of this, it has to be 
noticed that bone resorption and its regeneration using bone grafts 
and regenerative therapies are major clinical challenges in dentistry 
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and oral surgery. This makes the use of BPs for this application 
appealing under the condition that unfavorable side-effects can be 
avoided.
In view of the above mentioned, the effect of BPs on bone regeneration 
in osteoporotic animal models have already been evaluated in 
multiple studies. Takahata et al. studied the impact of systemic 
alendronate treatment on autologous bone graft in a vehicle for 
spinal fixation in ovariectomized (OVX) rats [12]. They showed BPs to 
inhibit endochondral ossification and to reduce graft as well as new-
formed bone resorption in osteoporotic rats compared to untreated 
animals due to the suppression of osteoclastic activity [12]. Using an 
osteoporotic sheep model, Verron et al. reported that local BP 
treatment for calcium phosphate grafted vertebral bone defects 
counteracted symptoms of osteoporosis by promoting new bone and 
increasing the bone area [10].
As mentioned before, BPs are the most commonly prescribed drugs to 
treat osteoporosis. The name of this group of drugs is derived from 
their composition, as their chemical structure is characterized by two 
phosphate groups covalently linked to carbon [13].  Further, the 
phosphorus-carbon-phosphorus backbone contains two side chains 
(called R1 and R2), which determine the mode of action and strength 
of the BPs. Considering the R-groups, two classes of BPs can be 
discerned, i.e. non-nitrogenous (no nitrogen in R2) and nitrogenous 
(nitrogen in R2). Non-nitrogenous BPs affect the cellular energy 
metabolism and initiate osteoclast apoptosis, resulting in reduction of 
bone breakdown. Nitrogenous BPs affect osteoclastogenesis, 
cytoskeletal dynamics and inhibit the formation of the ruffled border. 




compared with nitrogenous BPs. Zoledronic acid (ZA) is a nitrogenous 
BP and generally administered by intravenous (IV) infusion [14]. It is 
the most potent BP, demonstrating a very high affinity for 
hydroxyapatite crystals and possesses the longest retention to bone 
mineral in comparison to other BPs[15]. It has been hypothesized that 
ZA might interfere in bone turnover, which can result in enhancement 
of bone regeneration around bone substitutes by opposing the 
osteoclastic reduction of bone mineral density in osteoporosis. Recent 
animal studies have investigated the effects of IV and subcutaneously 
ZA administration in a healthy animal model [7, 15-18], but there are 
no published data regarding the long-term effect of systemically 
administered ZA on bone regeneration in bone defects grafted with a 
bone substitute in an osteoporotic animal model.
Accordingly, we hypothesized that an initial treatment of osteoporotic 
condition before bone defect preparation and bone substitute 
installation could enhance bone regeneration compared to a 
treatment started after this procedure. Therefore, the purpose of the 
present study was to evaluate bone regeneration in bone defects 
grafted with a bone substitute material in an osteoporotic rat model 
treated with intravenous ZA using three different treatment regimens 
(pre- bone grafting, post- bone grafting, and pre- and post- bone 
grafting) compared to non-treated controls. The obtained data can be 
used as a prelude for clinical steps focused on regeneration of maxilla-
facial bone defects.
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mATERIALs AND mEThODs
Animal and Ovariectomy (OVX) rat model
This study followed ethical standards as defined by the Committee for 
Ethical Animal Use at King Saud University, College of Dentistry, 
Kingdom of Saudi Arabia (Approval # 4/67/389683). A total of 24 
skeletally mature female Wistar rats (12 weeks of age and weighing 
approximately 250g) were used in this study. The animals were housed 
in standardized rat cages (3 – 4 animals per cage) maintained in a 
laboratory environment with controlled temperature (22˚C - 24˚C) and 
humidity (45% – 55%) and 12-hourly light and dark cycles with free 
access to a standard rat chow diet and water.
All animals were subjected to a bilateral ovariectomy (OVX) procedure 
under general anesthesia (GA) to induce osteoporosis, which has been 
described and reported before [19].
Surgical Procedure for Bone Graft Placement and study 
groups
Twelve weeks after ovariectomy, all animals underwent surgery under 
general anesthesia for bone graft placement in the left femoral 
condyle, as described previously [20] . Once anesthetized, the left hind 
limb of the rat was shaved and disinfected with Povidone-iodine 10% 
solution (Alphadine; Riyadh Pharma, Riyadh, Saudi Arabia). The knee 
capsule was incised longitudinally and the patellar ligament was 
gently elevated laterally. At the femoral intercondylar notch, a bone 
defect (3 mm in diameter and depth) was prepared using a surgical 
bur in a slow-speed rotary drill (800 rpm) (Elcomed 100, W&H 
Dentalwerk Burmoos GmbH, Austria). The bone defect was grafted 
with particulate inorganic bovine bone-substitute (InterOss®, 




cover the bovine-bone granules into the bone defect. Following 
placement of the bone graft, the soft tissue layers and skin were 
closed with VICRYL™ (4-0) polyglactin 910 resorbable Sutures (Ethicon, 
Johnson & Johnson, New Brunswick, New Jersey, USA). After surgery, 
animals were allowed to move unrestrictedly. 
The animals were divided and randomly distributed into four equal 
groups (n= 6 rats per group), according to the protocol for ZA 
administration. (Figure 1)
• ZA-Pre: weekly ZA administration (0.04 mg/kg body weight) in the 
4 weeks prior to bone graft placement.
• ZA-Post: weekly ZA administration in the 6 weeks from bone graft 
placement until the end of study.
• ZA-Pre+Post: weekly ZA administration from 4 weeks prior to bone 
graft placement until the end of the study.
• Saline: weekly intravenous injection with 1 ml physiological saline 
solution from 4 weeks prior to bone graft placement until the end 
of the study; this group was considered as non-treated controls. 
Zoledronic acid injection (0.04 mg/kg body weight) (Zometa 4 mg/5 
ml, Novartis, Basel, Switzerland) was prepared by mixing 0.05 ml of 
the drug with 0.95 ml normal saline (0.04 mg Zoledronic acid) [21] . 
The prepared solution was injected IV into the tail vein as per animal 
weight and according to study protocol. This dose of zoledronic acid 
was selected to mimic the cumulative clinical dose administered to 
human patients treated for osteoporosis [21] . Animals in the control 
group received 1ml saline solution through tail vein injection.
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Figure 1: Experimental animal groups and timeline for intravenous injections, surgical 
procedures and euthanasia in study animals.
Sample Retrieval and Specimen Preparation for Analysis
At the experimental endpoint (6 weeks after bone graft placement 
and 18 weeks since beginning of experiment), all rats were euthanized 
by CO2-suffocation in accordance with ethical standards. The left 
femoral bones were harvested and dissected from surrounding soft 
tissues. Subsequently, bone specimens were fixed in 10% neutral 
buffered formalin solution for 24 hours and then transferred to 70% 
isopropanol for further histological preparation and 
histomorphometric analysis.
Specimen preparation for hard tissue sectioning and 
histomorphometry
The femoral condyle specimens grafted with bone substitute (n = 6 
specimens per protocol) were embedded in freshly prepared 
poly(methyl methacrylate) (pMMA) resin. After polymerization, thin 
non-decalcified serial transversal sections (perpendicular to the long 
axis of the cylindrical bone defect) were cut at a thickness of ~10 μm 
using a sawing microtome (Leica SP-1600, Leica Microsystems 




described previously [22]. The non-decalcified sections were stained 
with methylene blue and basic fuchsin.
Histomorphometric examination
Digital images for all the stained sections were obtained and recorded 
using a light microscope (Aperio ImageScope, Leica Biosystems, 
Buffalo Grove, Illinois, USA), and used for descriptive and quantitative 
histological analysis. For histomorphometric analysis, a 3 mm 
diameter circular shape (area - 7.069 mm2), representing the region of 
interest (ROI), was superimposed onto the images of the bone defect. 
Using ImageJ software (Image processing and analysis in java 
freeware – Ver. 1.4; National Institutes of Health, Bethesda, Maryland, 
USA) the percentage area of newly formed bone (BA%) and remaining 
bone graft (RBG%) was measured as depicted in Supplementary Data 
S1. Always, three sections per tissue specimen were analyzed and the 
mean value of BA% and RBG% of these three sections was calculated.
Statistical analysis
Descriptive statistics including mean values and standard deviations 
were calculated for the quantitative variables BA% and RBG%. SPSS 
Statistical Program (Version 26, IBM, USA) was used for statistical 
analysis of the data. One-way analysis of variance (ANOVA) with 
Dunnett post-hoc test was used for comparison of the variables in 
each treatment group with saline group as control. The level of 
statistical significance was set at p<0.05.
REsULTs
Animal model
Healing progressed uneventfully in all study animals and no 
postoperative complications were observed during the experimental 
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period and at the time of euthanasia.
At the end of the study, six specimens of each experimental group 
were retrieved for histological preparation. Unfortunately, one of the 
specimens of the ZA Pre+Post group got lost due to problems with the 
embedding in PMMA (Table 1).










ZA-Pre 6 6 18
ZA-Post 6 6 18
ZA-Pre+Post 6 5# 13
Saline 6 6 18
#   1 sample excluded due to microscopic scan failure
Descriptive histological evaluation of bone defects 
(Figures 2&3)
Saline group: Light microscopic images confirmed the osteopenic 
character of the femoral condylar bone, which was characterized by 
the presence of sparse and discontinuous bone trabeculae with bone 
marrow in between these trabeculae. Remaining bovine bone particles 
could easily be recognized. Bone ingrowth into the defect area was 
very limited and mainly restricted to the edge of the defect. At the 
defect boundary, bone had grown into the spaces between the 




newly formed bone. Bone ingrowth did not proceed into the center of 
the defect, which was filled with fibrous tissue between the bovine 
bone particles. Osteoclast-like cells were observed in close contact 
with the bovine bone particles.
ZA-Pre group + ZA-Post group: The histological sections of the ZA-Pre 
and ZA-Post group specimens showed a very similar appearance. At 
low magnification, the femoral condylar bone was denser and more 
uniform compared to the Saline control group (Figure-2). In addition, 
the size of the intertrabecular voids was reduced. Bovine bone 
particles could still easily be recognized. In contrast to the Saline 
control group, bone had grown throughout the bone defect. The 
majority of the bovine bone particles was surrounded by a layer of 
bone, which was in tight contact with the surface of the bovine bone 
particles. Bone marrow-like tissue was present in between the newly 
deposited bone. Only very scarcely, osteoclast-like cells were observed.
ZA-Pre+Post group: Light microscopic analysis of the sections of the 
ZA-Pre+Post group showed again that the density of the femoral 
condylar bone was increased compared with the Saline control group. 
On the other hand, histological examination revealed a wide variation 
in bone defect healing compared to the ZA-Pre and ZA-Post group. In 
three specimens, bone formation into the defect space was similar to 
the ZA-Pre and ZA-Post specimens. Bone had grown from the defect 
border in between the bovine bone particles and was surrounding 
these particles. However, in two of the specimens, no bone ingrowth 
into the defect space had occurred. The bovine bone particles were 
still present, but were surrounded by fibrous tissue.
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Figure 2: Representative histological sections from different study groups showing a 
transverse section through the femoral condyle, perpendicular to the long axis of the 
cylindrical bone defect. Circular region depicting the region of interest (ROI) is shown 
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Histomorphometric analysis
BA% and RBG% was determined for the prepared histological 
specimens. One sample of the ZA-Pre+Post group was not included 
into the measurements due to failure of this specimen in the 
histological preparation procedure.
Data showed a mean percentage of BA% of 50.1%±3.5% for ZA-Pre, 
49.2%±8.2% for the ZA-Post, 40.7±16.0% for ZA-Pre+Post, and 
35.4%±5.4% for Saline control group. A repeated measures analysis of 
variance with Dunnett’s multiple comparison test indicated a 
significant difference in BA% between ZA-Pre and Saline control (p = 
0.031) and ZA-Post and Saline control (p= 0.043). ZA-Pre+Post group 
and Saline control group showed similar BA% (p = 0.663; Figure-4).
RBG% is considered to be a measure for the osteoclastic activity and 
dimensional stability of a bone substitute material. RBG% values were 
44.5%±8.8% for ZA-Pre, 47.1%±10.4% for ZA-Post, 36.3%±7.6% for ZA-
Pre+Post, and 42.3%±7.5% for Saline control group. No significant 
differences in RBG% existed between the various experimental groups 




Figure 4: Bar graphs with standard deviation indicating the mean quantitative 
histomorphometric values in the different study groups for bone area percentage (BA 
%). (statistically significant difference between the mean values – ** indicates p = 
0.031, * indicates p = 0.043).
Figure 5: Bar graphs with standard deviation indicating the mean quantitative 
histomorphometric values in the different study groups for remaining bone graft 
percentage (RBG %).
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DIsCUssION
The present study aimed to evaluate bone regeneration in bone 
defects grafted with a bone substitute material in an ovariectomized 
rat model treated with intravenous ZA via three different dosing 
regimens (pre-bone grafting, post-bone grafting, and pre+post-bone 
grafting). Ovariectomized rats receiving weekly saline injections 
served as controls. The study was conducted over a period of 18 
weeks, from ovariectomy via beginning of ZA injection until bone graft 
placement and finally euthanasia. The study time included a six-week 
healing period for the grafted bone defects. The harvested bone 
specimens were prepared for descriptive and quantitative histological 
examination. The data showed that the ZA-Pre and ZA-Post treatment 
resulted in a significant gain in BA% compared to saline controls. No 
evident effect of the ZA-Pre+Post treatment was found on BA%. 
Additionally, RBG% showed similar values for all experimental groups.
Experiments performed with animal species such as rabbits, cows, 
dogs, mice and rats are often used to study bone regeneration with 
the aid of bone substitutes. For mimicking osteoporotic bone 
conditions, predominantly rats are used, in which osteoporosis is 
induced via gonadectomy (i.e. orchidectomy for male and ovariectomy 
for female animals) Physiologically, gonadectomized rats possess an 
increased rate of bone turnover when compared to humans with 
osteoporosis. Nevertheless, they are excellent preclinical models for 
studying osteoporotic changes as they closely emulate 
pharmacotherapeutic response and allow studying the effect of 
estrogen depletion on the skeleton [19]. Currently, ZA is considered to 
be the most potent intravenous BP available for the treatment of 




Administration (USFDA) [23]. Guidelines for the required dose and 
administration route of ZA have been devised on basis of data from 
pre-clinical models and clinical practice[24]. Consequently, the current 
protocol for administration of ZA in osteoporotic patients follows a 
once yearly dosing regimen (5 mg IV) for maintenance of therapeutic 
drug levels and to facilitate patient compliance [25] . The duration of 
this therapy is limited to no more than three years. ZA is also 
administered in 4 mg dose to patients suffering from hypercalcemia 
and with advanced malignancies involving bone. ZA treatment by 
infusion for these patients is every 3-4 weeks. All patients receiving ZA 
infusion are advised to drink two glasses of water before and after IV 
infusion to ensure adequate hydration when receiving ZA in order to 
prevent adverse effects. The rats in the current study were 
administered 0.04 mg/kg body weight ZA IV every week for a duration 
of respectively four (ZA-Pre), six (ZA-Post), and ten weeks (ZA-
Pre+Post). No specific measures were taken for the hydration of the 
rats of before and after infusion. The posology and method of 
administration of the ZA-Pre and ZA-Post group was based on 
experience in previous studies [24, 26]. However, the dosage for the 
ZA-Pre+Post group was obtained by combining the dose of the ZA-Pre 
and ZA-Post group. It is known that the serum concentrations of ZA 
after IV infusion decrease rapidly due to the high affinity of ZA for 
bone mineral [27]. Additionally, the effect of ZA on osteoclasts is 
reported to be determined by dosage and administration frequency 
[27, 28]. This was confirmed by a clinical study involving patients with 
Paget’s disease, which reported a reduced therapeutic effect with ZA 
doses above 200 gr [29]. The serum alkaline phosphatase (SAP) level, 
which is an indicator for the therapeutic efficacy of ZA treatment, was 
significantly higher in patients treated with a high dose of ZA (>200 gr) 
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compared with patients treated with a lower dose of ZA (<200 gr). The 
histomorphometric analysis of our bone specimens revealed no 
significant difference in BA% between the ZA-Pre+Post and Saline 
control treatment group. Consequently, we suppose that the lack of 
effect of ZA infusion on BA% with this dosing regimen is due to an 
issue with the total administered dose. As previous work has shown 
that high doses of ZA (i.e. 66 mg/kg body weight; 3x weekly 
intraperitoneally during the 3 weeks prior to surgery) drastically 
decrease implant osseointegration [30], it seems likely that already 
the ZA-Pre+Post dosing regimen in the current study was too high. 
Therefore, we recommend that in future studies with ZA (as well as 
other BPs), the SAP level in the experimental animals is determined to 
assess the efficacy of the treatment.
The beneficial effect of BPs, like ZA treatment, on bone regeneration in 
an osteoporotic condition corroborates the existing literature [31]. The 
effect of these agents is known to be irrespective of their route of 
administration (i.e. systemically or locally)[32]. Additionally, several 
animal studies showed that BP therapy can also enhance bone volume 
and density in healthy animals. In these studies, bone defects in 
healthy animals were grafted with bone substitutes, followed by the 
administration of ZA either locally or systemically [15, 16]. Multiple 
studies reported that ZA treatment of the bone graft, locally and 
systemically, increased osteogenesis of the graft material and enabled 
bone formation [33]. Local ZA administration was found to be a highly 
efficient method of concentrating BPs at the site of bone graft 
placement and supported early bone formation as well as facilitated 
the biomechanical fixation of the bone substitute to the native bone 
[16, 34]. Further, Harding et al. used their rat bone chamber model to 




They showed that a single subcutaneous injection of 0.1 mg/kg ZA in 
rats significantly increased the volume of cancellous bone grafts 
installed in the bone chamber and protected the bone grafts against 
resorption [35]. Also, experiments demonstrated that just the soaking 
of an allograft in 4 μg/kg ZA solution increased bone volume and bone 
mineral density significantly over a 6 week healing period compared 
with sodium chloride soaked allograft [16, 34]. Our data of the ZA-Pre 
and ZA-Post group are in agreement with all these previous studies. 
This observation may be explained by the capacity of ZA to promote 
bone anabolism and prevent osteoclastic activity. In addition, BPs can 
increase the proliferation of osteo¬blasts and the synthesis of 
collagen and osteocalcin by bone cells at the cellular level [36]. 
Myoung et al. studied the effect of a BP on the expression of bone 
formation–specific genes after autogenous free bone grafting in rats. 
They found that the bisphosphonate reduced osteoclastic activity and 
induced osteoblasts to secrete an inhibitor of osteoclast- mediated 
resorption [37]. Also, in a different animal study, BP was given 
systemically at for 8 weeks and the authors found that alendronate 
stimulated bone formation in the autogenous bone grafts [38]. The 
histomorphometric analysis for remaining bone graft material showed 
no differences between the various treatment groups and the Saline 
control group. This observation is not in line with the supposed 
mechanism of action of ZA, which acts as an inhibitor for 
osteoclastogenesis. A reduced number of osteoclasts will result in a 
decreased degradation rate of the applied bone substitute [39]. 
Histology indeed confirmed the scarce presence of osteoclasts in the 
bone specimens of the ZA-Pre and ZA-Post group. On the other hand, 
light microscopic examination of the Saline control group samples 
revealed the presence of osteoclasts and still the resorption of the 
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bovine bone particles was not pronounced after 6 weeks of 
implantation. In view of the limited biodegradation capacity of bovine 
bone particles as reported in several publications [40, 41], the current 
data confirm that inorganic bovine bone substitute is very stable and 
not easily replaced by newly formed bone [42].
Although the results of the current animal study demonstrate the 
efficacy of ZA administration as a therapeutic strategy for the 
regeneration in artificially created bone defects in an osteoporotic 
condition, it has to be noticed that ovariectomized rats have a faster 
bone turnover than patients with osteoporosis. This limitation shall 
apply prior to clinical translation of the present study results. 
Therefore, further in vivo studies are necessary to clinically validate 
the effect of long-term ZA administration on bone substitutes healing.
CONCLUsION
In conclusion, our data show that pre- as well as post-surgical 
intravenous administration of ZA positively influences the healing of 
bone defects created in ovariectomized rats and grafted with 
inorganic bovine bone substitute. On the other hand, no significant 
difference in the bone repair process was found for continued ZA 
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Supplement	  1:	  	  




How	  region	  of	  interest	  (ROI)	  created	  in	  STANDARD	  manner:	  
Using	   the	   Aperio	   ScanScope	   image	   extraction	   tool,	   individual	   histology	   image	  was	  
extracted	  in	  25%	  jpg	  format.	  	  
Next,	   we	   selected	   the	   optimal	   sliced	   and	   scanned	   implant	   (from	   our	   implants	  
projects),	   the	   implant	  physical	  measurement	   is	  3mm	  and	  7.069mm2	  as	   standardize	  
reference.	  	  
In	  ImageJ	  or	  Adobe	  Photoshop,	  we	  drew	  a	  horizontal	  line	  at	  the	  square	  midpoint	  and	  
measured	   the	   length	   yielding	   3mm	   in	   3060px,	   therefore	   1mm	   is	   1020px.	  
The	  3060px	  measurement	   was	   used	   to	   draw	   a	   perfect	   3mm	   circle	   selection	   with	  
7.069mm2.	  	  





How	   Percentage	   new	   bone	   area	   (BA	  %)	   and	   Percentage	   area	   of	   remaining	   bone	  
graft	  (RBG	  %)	  estimated	  in	  STANDARD	  manner:	  
	  
Histomorphometric	  analysis	  of	  the	  non-­‐decalcified	  sections	  was	  used	  combined	  with	  
ImageJ	  analysis:	  	  
(a) Percentage	  new	  bone	  area	  (BA	  %)	  determined	  by	  standardizing	  the	  hue	  and	  
saturation	  of	   bone	   tissue	   in	   red	   color	   and	   then	  area	  measurement	  digitally	  
recognized	  in	  yellow	  color	  
(b) Percentage	   area	   of	   remaining	   bone	   graft	   (RBG	   %)	   determined	   by	  
standardizing	  the	  hue	  and	  saturation	  of	  bone	  graft	  particles	  in	  red	  color	  and	  
then	   area	   measurement	   digitally	   recognized	   in	   yellow	   color.	   For	   all	  
quantitative	   analyses,	   histological	   verification	   (based	   on	   tissue	  morphology	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Defining	  a	  circular	  region	  of	  interest	  (ROI)	  measuring	  3	  mm	  in	  diameter	  









































Percentage	  new	  bone	  area	  (BA	  %)	  estimated	  by	  standardizing	  the	  hue	  and	  
saturation	  of	  bone	  tissue	  in	  red	  color	  and	  then	  area	  measurement	  digitally	  








Percentage	  area	  of	  remaining	  bone	  graft	  (RBG	  %)	  estimated	  by	  standardizing	  the	  
hue	  and	  saturation	  of	  bone	  graft	  particles	  in	  red	  color	  and	  then	  area	  











sUmmARy AND ADDREss TO ThE AIms
Chapter 1: General introduction
Alveolar bone is a supporting tissue that develops in conjunction with 
the eruption of the teeth [1]. Subsequent to the extraction of teeth, the 
alveolar bone will undergo atrophy because of the bundle bone at the 
extraction site obviously will lose its function and disappears [2]. In 
addition, loss of alveolar bone can be associated with periodontal 
disease, peri-apical pathology, or injury to teeth. A so-called bone-
grafting procedure is applied to promote the regeneration of the lost 
alveolar bone [3]. Bone grafting involves using natural or synthetic 
bone substitutes to stimulate healing of bone through three different 
mechanisms: osteogenesis, osteoconduction and osteoinduction [4]. 
However, bone regeneration is challenged in a condition of altered 
bone metabolism, like in osteoporosis. The exact negative effect of 
altered bone metabolism on the bone healing process in association 
with a bone grafting procedure has not been fully characterized. Thus, 
the current preclinical research work was devoted to study bone 
healing in grafted osseous defects created in a healthy and 
osteoporotic rat model. Additionally, this thesis aimed to investigate 
the therapeutic effect of systemic administration of anti-osteoporotic 
drugs on bone regeneration in adjunction with bone grafting 
procedures. Below, the sub-aims of the present dissertation are listed, 
each followed by the summary of the performed experimental work to 
address these sub-aims.
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Chapter 2: Evaluation of the effect of induction of 
osteoporosis after initial healing of bone defects grafted 
with bovine-bone granules.
Since osteoporotic conditions are known to alter bone metabolism 
and supposed to affect bone regeneration related to bone defect 
grafting, this chapter aimed to evaluate the effect of osteoporotic 
induction after 8-weeks of initial healing of bone defects grafted with 
InterOss® granules in a rat model. Bone defects were created in the 
femoral condyles of female Wistar rats and filled with xenograft 
(InterOss®) granules. After 8 weeks of bone healing, rats were 
randomly ovariectomized (OVX) or sham-operated (SHAM). At 14 
weeks of bone healing, histological and histomorphometric analyses 
of bone specimens assessed new bone formation (N-BF%), remaining 
bone graft (RBG%), and trabecular bone space (Tb.Sp%) within the 
defect area. Osseous defects grafted with InterOss® granules 
exhibited significantly less N-BF% and RBG% in OVX rats compared to 
SHAM rats. Histological evaluation revealed a significant alteration in 
the trabecular bone space; Tb.Sp% was higher in OVX compared to 
SHAM rats. In conclusion, chapter 2 demonstrated inducing an 
osteoporotic condition in rats after initial healing of a bone graft 
material negatively influences bone regeneration in the created bone 
defect.
Chapter 3: A meta-analytical approach to address the use 
of anti-osteoporotic drugs with bone grafting in animal 
models.
Clinically, the mission of regenerative dentistry is restoring damaged 
alveolar bone in both healthy and medically compromised patients. 
The key step in alveolar bone regeneration is to stimulate a cascade of 




of anti-osteoporotic drugs has been reported as an approach to favor 
early bone healing in bone defect regeneration in osteoporotic 
condition. This meta-analysis assessed the data available in preclinical 
studies to quantify literature evidence on anti-osteoporotic drug 
(different types and different route of administration) efficacy toward 
bone regeneration in adjunction with bone grafting in healthy and 
osteoporotic conditions. In chapter 3, a PubMed and EMBASE (via 
OvidSP) search for publications resulted in 60 animal studies for 
inclusion in a meta-analysis. The studies were assessed for reporting 
quality and risk of bias. Outcome data from selected studies were 
categorized as either experimental (bone grafting with the 
administration of anti-osteoporotic drugs) or control. The primary 
outcomes variables were histomorphometric bone area (BA%) and 
micro-CT bone volume (BV%). In this review, several animal models (52 
healthy, 6 osteoporotic, and 2 both conditions) were subjected to 
examine the effect of anti-osteoporotic drugs on bone grafting, with a 
predominant use of rodent species.
A random-effects meta-analysis revealed a significant increase in 
overall BA% and BV% due to osteoporotic drug treatment compared 
with controls. For subgroups, both routes of anti-osteoporotic drug 
administration showed similar effects on BA%. In contrast, systemic 
anti-osteoporotic drug administration led to significantly higher BV% 
compared with local administration. Further, administration of 
anabolic drugs significantly increased BA% compared with anti-
catabolic drugs. Chapter 3 concluded that (1) using the anti-
osteoporotic drugs in adjunction with grafting stimulated bone 
regeneration, and (2) not all studies showed a positive effect and the 
present results need to be applied with care, as the included papers 
showed experimental heterogeneity for animal models.
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Chapter 4: Biological effect of single or combined drug 
therapy on bone regeneration: An in vivo study in healthy 
and osteoporotic rats.
Complications regarding bone regeneration in patients with systemic 
impaired bone metabolism (e.g. osteoporosis) represent a rapidly 
increasing clinical challenge. Alendronate and simvastatin are drugs 
commonly used to promote bone metabolism in osteoporotic 
conditions. This chapter aimed to evaluate initial bone regeneration 
within osseous defects grafted with beta-tricalcium phosphate (β-TCP) 
in adjunction with single or combined therapy using alendronate and 
simvastatin (i.e. daily subcutaneous injection for 3 weeks) in healthy 
and osteoporotic rats. Eighty Wistar female rats were used, either 
ovariectomized (OVX; n=40) or sham operated (n=40). Six weeks later, 
osseous defects were created in the left femoral condyles, grafted 
with β-TCP and then subcutaneous injection of alendronate and 
simvastatin, alone or in combination was started for all OVX and sham 
animals daily for 3 weeks. A control group received subcutaneous 
saline. At the end of the 3 weeks, specimens were harvested for 
histological preparation. Histomorphometric measurements were 
done, i.e. bone area (BA%) and remaining bone graft (RBG%). Results 
showed the following: (1) in osteoporotic rats, 3-weeks of daily 
subcutaneous injection of combined therapy (alendronate plus 
simvastatin) led to a significant increase in BA% and a significant 
decrease in RBG% compared to healthy controls in osseous defects 
grafted with β-TCP. (2) No significant differences in BA% and RBG% 
were found in the osteoporotic rats for single treatments. (3) Healthy 
controls showed similar BA% and RBG% upon single or combined 
therapy compared to non-treated control rats. This chapter concluded 




plus simvastatin) results in significantly increased new bone formation 
(BA%) within osseous defects grafted with β-TCP in osteoporotic rats 
during a three weeks healing period.
Chapter 5: Effect of systemic zoledronic acid dosing 
regimens on bone regeneration in osteoporotic rats.
One of the greatest challenges associated with alveolar bone 
augmentation is bone resorption, which is further potentiated by 
skeletal disorders such as osteoporosis. Bisphosphonates (BP) are the 
preferred pharmacotherapy for osteoporosis treatment. Zoledronic 
acid (ZA) is a new generation intravenous BP that counteracts 
osteoporosis on two fronts by decreasing bone resorption and 
encouraging bone anabolism. Accordingly, the objective of this study 
was to evaluate the regeneration of bone defects created in the 
femoral condyle of osteoporotic rats, which were systemically treated 
via intravenous (IV) dosing regimens of ZA and compared to non-
treated controls. Twenty-four female Wistar rats were ovariectomized 
(OVX). After confirming osteoporotic condition, bone defects were 
created in the left femoral condyle of all rats (one defect per rat). All 
defects were grafted with particulate xenograft bone substitute. Rats 
were IV injected on a weekly basis with ZA (0.04 mg/kg body weight) 
according to the following dosing regimens: (1) Group ZA-Pre (n=6 
rats) was injected with ZA starting four weeks before creation of the 
bone defect, (2) Group ZA-Post (n=6 rats) was injected with ZA 
immediately after bone defect preparation and continued until the 
end of experiment, and (3) Group ZA-Pre+Post (n=6 rats) received IV 
ZA 4 weeks before creation of the bone defect and ZA administration 
was continued until the end of experiment. A control group (n=6 rats) 
was included in the study, which was injected with physiological saline 
solution (Group-Saline). At 6 weeks post-defect preparation, the 
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femoral condyle specimens were harvested for histomorphometric 
assessment for bone area percentage (BA%) and remaining bone graft 
percentage (RBG%). Data revealed that BA% for ZA-Pre (50.1% ± 3.5%) 
and ZA-Post (49.2% ± 8.2%) treatment was significantly increased 
compared to Saline control. In contrast, ZA-Pre+Post (40.7% ± 16.0%) 
treatment showed a similar BA% compared to saline control 
treatment. For RBG%, all experimental groups showed similar results 
ranging from 36.3 to 47.1%. This chapter indicated that pre- or post-
surgical systemic IV administration of ZA improved bone regeneration 
of bone defects grafted with xenograft bone particles in osteoporotic 
bone conditions. However, no favourable effect on bone repair was 




CLOsING REmARKs AND fUTURE 
pERspECTIVEs
In dentistry, already a lot of research has been done to investigate the 
bone formation supportive effect of bone substitutes in experimentally 
created bone defects in various animal models. However, healthy 
animals were used in most of these studies. On the other hand, the 
knowledge on bone regeneration in a compromised condition is 
limited. Still, it is known that bone substitutes are frequently used in 
patients that show a reduced healing capacity due to underlying 
medical problems. In view of this, there is a clear need to research that 
addresses bone regeneration aspects in challenged bone conditions 
(like e.g. osteoporosis). Consequently, the current research focused on 
bone healing of osseous defects in healthy and osteoporotic condition 
as well as the possible advantage of systemic administration of anti-
osteoporotic drugs on bone regeneration.
In conclusion, the presented results in this thesis revealed that 
inducing an osteoporotic condition in rats negatively influences bone 
regeneration in a created bone defect. Further, we observed that anti-
osteoporotic drugs, i.e. BPs, can favourably support bone regeneration 
depending on the administered dose as well as the timing of 
administration.
Disturbed bone regeneration in osteoporotic conditions
In a normal metabolic condition, bone regeneration occurs through 
well-balanced activity and precise coordination of osteoblasts and 
osteoclasts. Disturbed bone regeneration/metabolism is often 
associated with the occurrence of a pathological bone disease, like 
osteoporosis. Despite available knowledge on osteoporosis, its 
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influence on bone regeneration in relation to bone grafting is still less 
understood. In addition, no information is available about how 
osteoporosis affects bone regeneration in grafted defects if 
osteoporosis onset is after graft installation. As reported in Chapter 2, 
inducing an osteoporotic condition in preclinical animals after initial 
healing of a bone graft material negatively influences bone 
regeneration in the created bone defect, as confirmed by histological 
and histomorphometric examination. However, the exact underlying 
biological mechanism of these findings was not investigated. A better 
understanding of the involved pathophysiological process in relation 
to bone regeneration in an artificially created bone defect is required, 
as our observations in Chapters 4 and 5 demonstrated that the 
unfavourable effect of osteoporosis can be overcome by the 
administration of anti-osteoporotic drugs. However, the influence of 
these agents is depending on type, dose and timing of administration. 
Therefore, in depth cellular and molecular investigations are 
recommended to explore the distinctive characteristics of osteoporosis 
in relation to bone defect healing. Such research is also very relevant 
in view of the potential and safe clinical application of anti-
osteoporotic drugs in bone grafting procedures in osteoporotic 
conditions.
Properties of an ideal bone substitute for bone 
regeneration
Clinically, several bone regenerative approaches can be applied to 
successfully treat osseous defects. However, the ideal bone substitute 
should not evoke an adverse immune response. Further, they must be 
able to maintain their volume over a predictable time period, but have 
to disappear during time to avoid a negative effect on the mechanical 




material has to possess a well-controlled biodegradability. Another 
crucial property for an ideal bone grafting material is that it has to 
induce angiogenesis, which regulates bone formation [6]. Oxygen and 
the presence of angiogenic factors are known to interact with bone 
cells and are required to achieve successful bone healing. In addition, 
bone substitutes should be not costly. Unfortunately, none of the 
currently available bone substitute materials have all these desirable 
features. Nevertheless, the problems associated with human 
transplanted bone grafts have increased the use of xenograft (e.g. 
bovine bone particles) and synthetic bone substitutes (e.g. beta-
calcium phosphate, β-TCP). As confirmed by our histological and 
histomorphometric assessments in Chapters 2, 4 and 5, the used 
biomaterials indeed did not have a negative effect on the regeneration 
of the created bone defects. On the other hand, they did not have an 
additional bone formation promotive effect in the presence of an 
osteoporotic condition. With respect to this, our findings support the 
requirement that bone-grafting materials need to elicit regenerative 
capabilities. Such a bone formation promotive role is very relevant for 
patients with underlying bone pathologies to reduce the healing time 
and make the outcome of the healing process more predictable. In 
addition to the systemic administration of anti-osteoporotic agents, 
we recommend that further research is done to the potential of 
incorporating these drugs in bone substituting materials and their 
effect after local release.
Pharmacological enhancement of bone augmentation
Research carried out in the present thesis has put in evidence the 
significant therapeutic potential of anti-osteoporotic drugs for bone 
grafting healing in an osteoporotic condition. The clinically applied 
167
Summary, Closing Remarks, and Future Perspectives
6
anti-osteoporotic drugs are mainly anti-catabolic agents (e.g. BPs) 
and anabolic agents (e.g. simvastatin). As one of the most common 
bisphosphonates, alendronate and zoledronic acid have been used in 
Chapters 4 and 5 to stimulate in vivo bone formation in adjunction 
with bone substitutes. Although their molecular mechanisms are not 
clearly understood, these drugs are originally intended to reverse bone 
loss in osteoporotic condition by altering bone metabolism. However, 
as mentioned above, unravelling the determinants of metabolic bone 
disorders and its specific pathophysiological mechanisms was not the 
aim of the current thesis. Therefore, we recommend that in a 
prospective manner several issues related to the mechanism of action 
of BPs on bone healing in adjunction with bone substitute grafts is 
solved prior to the initiation of clinical trials.
Interestingly, combined therapy (alendronate plus simvastatin) in 
adjunction with bone grafting also resulted in a significant increase in 
bone regeneration in osteoporotic conditions based on our histological 
assessment (Chapter 4). For successful clinical application, it is 
important to consider that such observations are depending on the 
dosing regimen and administration frequency of drugs, the 
pharmacokinetics of drugs, the size of the bone defect as well as the 
type of bone substitute and its regenerative capacity. These biological 
and materials concerns should be prospectively investigated and 
validated prior to clinical translation of the present thesis results.
In vivo experimental model and limitations
Experiments performed with animal species such as rabbits, goats, 
sheep, dogs, and rodents are often used to study bone regeneration. 
For mimicking osteoporotic bone conditions, rat animals have been 




regeneration following induced oestrogen deficiency as in human. 
Although rats are small experimental animals and have a different 
bone formation and remodelling rate compared with humans, they 
are excellent preclinical models for studying osteoporotic changes as 
they closely emulate pharmacotherapeutic response and allow to 
study the effect of oestrogen depletion on the skeleton [7].
In our various experiments, we were able to examine the effect of anti-
osteoporotic drugs on bone regeneration related to bone grafts in a 
direct comparison by using both animals with osteoporotic conditions 
and healthy animals in one single study. However, it has to be noticed 
that the preclinical model as used in the present thesis encounters 
several limitations that need to be solved in prospective studies. For 
instance, it has been noticed that ovariectomized rats have a faster 
bone turnover than patients with osteoporosis. In addition, we 
performed short-time studies, while long-term maintenance of the 
favourable effect of the drugs is important for safe clinical application. 
Therefore, further in vivo studies can be suggested to validate the 
effect of long-term administration of anti-osteoporotic drugs on bone 
regeneration related to different bone substitutes. In addition, a larger 
animal model should be used to clarify the effect of anti-osteoporotic 
drugs in adjunction with bone graft under challenged bone condition.
Further, we have to emphasize that the experimental osteoporotic rats 
in the present thesis were mainly fed with a high calcium diet, which 
may (partly) reverse the condition of osteopenia in ovariectomized 
animals [8].
Our purpose was to mimic the clinical condition, as osteoporotic 
patients are used to eat healthy food with sufficient amounts of 
calcium and vitamin D. Still, the effect of diet should be highly 
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considered in prospective research efforts.
Finally, the biological benefit of anti-osteoporotic drugs on bone 
regeneration is expected to be affected by the type of graft material 
(natural vs. synthetic) and their chemical composition and 
degradation. However, the nature and characteristics of the used 
bone graft materials was not the focus in the comparative analysis in 
the present research. This issue warrants further in vivo investigation 
into the individual effects of different bone substitute materials along 
with anti-osteoporotic drugs in healthy and osteoporotic animal 
models.
In summary, our experiments indicated that the administration of BPs 
can support the healing of bone defects in the presence of an 
osteoporotic condition. However, this effect is depending on the 
appropriate dose and timing of the BP administration. Despite this 
favorable outcome, our research included some limitations, which 
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HOOFDSTUK 6
Samenvatting, Afsluitende Opmerkingen En 




sAmENVATTING EN bEspREKING VAN DE 
DOELEN
Hoofdstuk 1: Algemene introductie
Alveolair bot is een ondersteunend weefsel dat ontwikkelt in 
combinatie met de eruptie van de tanden [1]. Na het uittrekken van 
tanden ondergaat het alveolair bot atrofie omdat het bundelbot bij de 
extractieplek natuurlijk zijn functie zal verliezen en verdwijnen [2]. 
Tevens kan het verlies van alveolair bot worden geassocieerd met 
paradontale aandoening, periapicale pathologie, of letsel aan de 
tanden. Er wordt een zogenaamde bottransplantatie toegepast om 
het opnieuw genereren van het verloren alveolair bot te bevorderen 
[3]. Een bottransplantatie wordt gedaan met natuurlijk bot of 
synthetische vervangin daarvan om het genezen van het bot door 
middel van drie verschillende mechanismen te stimuleren: 
osteogenese, osteoconductie en osteoinductie [4]. Botgeneratie wordt 
echter bemoeilijkt in geval van een gewijzigd botmetabolisme, zoals 
bij osteoporose. Het exacte negatieve effect van gewijzigd 
botmetabolisme op het genezingsproces van het bot in associatie met 
een bottransplantatie is nog niet helemaal duidelijk. Het huidige 
preklinische onderzoekswerk was gericht op het bestuderen van het 
genezen van bot in getransplanteerde benige defecten in een gezond 
en osteoporotisch ratmodel. Bovendien had deze these tot doel het 
onderzoeken van het therapeutische effect van systematisch 
toediening van anti-osteoporotische medicijnen op botgeneratie 
gerelateerd aan bottransplantaties. In het onderstaande worden de 
subdoelen van de huidige dissertatie genoemd, elk van hen gevolg 
door de samenvatting van het uitgevoerd experimentele werk ter 
behandeling van deze subdoelen.
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Hoofdstuk 2: Evaluatie van het effect van inductie van 
osteoporose na het eerste genezen van botaandoeningen 
getransplanteerd met boviene botgranulaten.
Aangezien osteoporotische condities erom bekend staan het 
botmetabolisme te wijzigen en verondersteld worden botregeneratie 
gerelateerd aan bottransplantatie negatief te beïnvloeden, heeft dit 
hoofdstuk als doel het evalueren van het effect van osteoporotische 
inductie na 8 weken van genezing van botdefecten getransplanteerd 
met granulaten van InterOss(r) in een ratmodel. Er werden botdefecten 
gecreëerd in de femorale condylus van vrouwelijke Wistar-ratten en 
gevuld met xenotransplantatie (InterOss®) granulaten. Na 8 weken 
van botgenezing, werden bij ratten willekeurig de eierstokken 
verwijderd (OVX) of ondergingen ze een schijnoperatie (SHAM).  Na 14 
weken van botgenezing, evalueerden histologische en 
histomorfometrische analyses van botspecimen nieuwe botvorming 
(N-BF%), resterende bottransplantatie (RBG%), en trabeculaire 
botruimte (Tb.Sp%) binnen het defecte gebied. Benige defecten 
getransplanteerd met granulaten van InterOss® toonden significant 
minder N-BF% en RBG% in OVX-ratten in vergelijking met de SHAM-
ratten. Histologische evaluatie legde een significante wijziging in de 
trabeculaire botruimte bloot; Tb.Sp% was hoger in OVX in vergelijking 
met SHAM-ratten. Concluderend kunnen we zeggen dat hoofdstuk 2 
aantoonde dat het toebrengen van een osteoporotische conditie van 
ratten na het eerste genezen van bottransplantatiemateriaal een 





Hoofdstuk 3: Een meta-analytische benadering voor het 
bespreken van het gebruik van anti-osteoporotische 
medicatie met bottransplantatie in diermodellen.
Klinisch gezien, is de missie van regeneratieve tandheelkunde het 
herstellen van beschadig alveolair bot in zowel gezonde patiënten als 
patiënten met een verminderde medische gezondheid. De 
belangrijkste stap in het regenereren van alveolair bot is het 
stimuleren van een opeenvolging van genezende gebeurtenissen, die 
de hoeveelheid en kwaliteit van bot bevorderen.  Het gebruik van anti-
osteoporotische medicatie is vermeld als een benadering voor het 
begunstigen van vroege botgenezing in botregeneratie bij een 
osteoporotische conditie. Deze meta-analyse evalueerde de gegevens 
beschikbaar in preklinisch onderzoek voor het kwantificeren van 
bewijs in literatuur over de werkzaamheid van anti-osteoporotische 
medicatie (verschillende typen en verschillende routes van toediening) 
richting botregeneratie in combinatie met bottransplantatie in 
gezonde en osteoporotische condities. In hoofdstuk 3, leidde een 
PubMed en EMBASE (via OvidSP) zoekopdracht naar publicaties tot 60 
dieronderzoeken voor opname in een meta-analyse. De onderzoeken 
werden geëvalueerd op de kwaliteit van de rapportage en het risico 
op vooringenomenheid. De uitkomsten van geselecteerde 
onderzoeken werden gecategoriseerd als experimenteel 
(bottransplantatie met het toedienen van anti-osteoporotische 
medicatie) of als controle. De primaire uitkomstvariabelen waren 
histomorfologisch botgebied (BA%) en micro-CT botvolume (BV%). In 
deze evaluatie werden enkele diermodellen (52 gezond, 6 
osteoporotisch, en 2 met beide condities) blootgesteld om het effect 
van anti-osteoporotische medicatie en bottransplantatie te 
onderzoeken, waarbij overwegend knaagdiersoorten werden gebruikt.
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Een meta-analyse met willekeurige effecten liet een significante 
toename in de algehele BA% en BV% zien als gevolg van behandeling 
met osteoporotische medicatie in vergelijking met de controlegroep. 
Voor subgroepen geldt dat beide routes van toediening van anti-
osteoporotische medicatie dat soortgelijke effecten op BA% werden 
waargenomen. Daartegenover stond dat het systematisch toedienen 
van anti-osteoporotische medicatie tot een significant hogere BV% 
leidde in vergelijking met locale toediening. Bovendien leidde het 
toedienen van anabolische medicatie tot een toename van BA% in 
vergelijking met antikatabolische medicatie. Hoofdstuk 3 kwam tot de 
conclusie dat (1) het gebruik van de anti-osteoporotische medicatie in 
combinatie met transplantatie de botregeneratie stimuleerde, en (2) 
dat niet alle onderzoeken een positief effect aantoonden en dat het 
huidige resultaat met voorzichtigheid moet worden toegepast, 
aangezien de bijgevoegde documentatie experimentele heterogeniteit 
aantoonde voor de diermodellen.
Hoofdstuk 4: Biologische effect van een enkele of 
gecombineerde medicinale therapie op botregeneratie: Een 
in vivo-onderzoek in gezonde en osteoporotische ratten.
Complicaties met betrekking tot botregeneratie in patiënten met 
systemisch aangetast botmetabolisme (bijvoorbeeld oeseoporose) 
vertegenwoordigen een snel groeiende klinische uitdaging. 
Alendronaat en Simvastatine zijn medicijnen vaak gebruikt om 
botmetabolisme in osteoporotische condities te bevorderen. Dit 
hoofdstuk had als doel het evalueren van de eerste botregeneratie 
binnen benige defecten getransplanteerd met beta-tricalciumfosfaat 
(ß-TCP) in combinatie met een enkele of een gecombineerde therapie 
waarbij Alendronaat en Simvastatine worden gebruikt (d.w.z. een 




osteoporotische ratten. Tachtig Wistar-vrouwelijke ratten werden 
gebruikt, met verwijderde eierstokken (OVX; n=40) of een 
schijnoperatie (n=40). Zes weken later werden er benige defecten 
gecreëerd in de linkerfemorale condylus, getransplanteerd met ß-TCP 
en daarna een onderhuidse injectie van Alendronaat en Simvastatine, 
alleen of in combinatie werd begonnen voor alle OVX en de dieren die 
schijnoperatie hadden ondergaan, en dit 3 weken lang. Een 
controlegroep kreeg een onderhuidse zoutoplossing toegediend. Aan 
het einde van deze 3 weken, werden specimen verzameld ter 
histologische preparatie. Histomoformetische metingen werden 
uitgevoerd, d.w.z. het botgebied (BA%) EN resterend bottransplantaat 
(RBG%). De resultaten waren als volgt: (1) in osteoporotische ratten, 
leidde het 3 weken lang dagelijks toedienen van een onderhuidse 
injectie in een gecombineerde therapie (Alendronaat plus 
Simvastatine) tot een significante toename in BA% en een significante 
afname van RBG% in vergelijking met de gezonde controlegroep in 
benige defecten getransplanteerd met ß-TCP. (2) Er werden geen 
significante verschillen in BA% en RBG% aangetroffen in de 
osteoporotische ratten bij enkelvoudige behandelingen. (3) De 
gezonde controlegroep toonde een soortgelijke BA% en RBG% bij 
enkelvoudige of gecombineerde therapie in vergelijking met de niet-
behandelde controle ratten. Dit hoofdstuk kwam tot de conclusie dat 
dagelijkse onderhuidse injecties voor een gecombineerde therapie 
(Alendronaat plus Simvastatine) leidde tot een significante toename 
van nieuwe botvorming (BA%) binnen benige defecten 
getransplanteerd met ß-TCP in osteoporotische ratten gedurende een 
genezingsperiode van drie weken.
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Hoofdstuk 5: Effecten van structureel zoledronaat 
doseerregiem op botregeneratie in osteoporotische ratten.
Een van de grootste uitdagingen geassocieerd met alveolaire 
botaugmentatie is botresorptie, iets dat verder wordt versterkt door 
aandoeningen aan het skelet zoals osteoporose. Bisfofonaat (BP) is de 
farmacotherapie die de voorkeur hebben bij het behandelen van 
osteoporose. Zoledronaat (ZA) is een intraveneuze BP van een nieuwe 
generatie dat osteoporose op twee fronten bestrijdt door de 
botresorptie te verminderen en het bevorderen van botanabolisme. 
Dienovereenkomstig, was het doel van deze studie het evalueren van 
de regeneratie van botdefecten gecreëerd in de femorale condylus 
van osteoporotische ratten, die structureel werden behandeld via een 
intraveneuze (IV) doseerregiem van ZA en werden vergeleken met een 
niet-behandelde controlegroep. Vierentwintig vrouwelijke Wistar-
ratten werden ontdaan van hun eierstokken (OVX). Na het bevestigen 
van de osteoporotische conditie, werden er botdefecten gecreëerd in 
de linkerfemorale condylus in alle ratten (één defect per rat). Alle 
defecten werden getransplanteerd met botsubstituten van granulaten 
xenotransplantatie. Ratten werden IV wekelijks geïnjecteerd met ZA 
(0,04 mg/kg lichaamsgewicht) volgens het volgende doseerregieme: 
(1) Groep ZA-Pre (n=6 ratten) werd geïnjecteerd met ZA waarmee 
werd begonnen vier weken voor het creëren van het botdefect, (2) 
Groep ZA-Post (n=6 ratten) werd onmiddellijk na de preparatie van het 
botdefect geïnjecteerd met ZOL en dit bleef gebeuren tot het einde 
van het experiment, en (3) Groep ZA-Pre+Post (n=6 ratten) kreeg ZA 4 
weken vóór het creëren van het botdefect en het toedienen van ZOL 
bleef doorgaan tot het einde van het experiment. Een controlegroep 
(n=6 ratten) werd opgenomen in het onderzoek, en deze groep werd 




weken post-defect preparatie, werden de femorale condylus specimen 
verzameld voor histomorfologische evaluatie voor het percentage van 
het botgebied (BA%) en de resterende percentage bottransplantatie 
(RBG%). De verkregen resultaten toonde aan dat BA% voor ZA-Pre 
(50,1% -/+ 3,5%) en ZA-Post (49,2% -/+ 8,2%) behandelingen significant 
was toegenomen in vergelijking met de Saline controlegroep. 
Daarentegen, toonde de ZA-Pre+Post (40,7% -/+16,0%) behandeling 
een soortgelijke BA% vergeleken met de behandeling van de Saline 
controlegroep. Voor RBG% geldt dat alle experimentele groepen 
soortgelijke resultaten vertoonden variërend van 36,3 tot 47,1%. Dit 
hoofdstuk gaf aan dat pre- of postoperatieve structurele intraveneuze 
toediening van ZA de botregeneratie van bottransplantatie met 
defecten met botdeeltjes van xenotransplantatie in osteoporotische 
condities verbeterde. Geen gunstige effecten op het herstel van het 
bot werden echter waargenomen bij gecontinueerd pre- plus 
postoperatieve ZA-behandeling.
AfsLUITENDE OpmERKINGEN EN 
pERspECTIEVEN VOOR DE TOEKOmsT
In de tandheelkunde is reeds veel onderzoek gedaan naar het 
ondersteunende effect van botvorming bij botsubstituten in 
experimenteel gecreëerde botdefecten in verschillende diermodellen. 
In de meeste van deze onderzoeken werden echter gezonde dieren 
gebruikt. Aan de andere kant, de kennis over botregeneratie in een 
aangetaste conditie is beperkt. Niettemin, het is bekend dat 
botsubstituten regelmatig worden gebruikt in patiënten die een 
verminderde genezingscapaciteit hebben als gevolg van 
onderliggende medische problemen. Vanuit dat perspectief, is er 
duidelijk behoefte aan onderzoek dat zich richt op de aspecten van 
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botregeneratie in slechte botcondities (bijvoorbeeld osteoporose). 
Bijgevolg, richtte het huidige onderzoek zich op botgenezing van 
benige defecten in een gezonde en osteoporotische conditie en ook op 
het mogelijke voordeel van structurele toediening van anti-
osteoporotische medicatie op botregeneratie.
Concluderend kunnen we zeggen dat resultaten in deze these 
aantoonde dat het toebrengen van een osteoporotische conditie in 
ratten een negatieve invloed heeft op botregeneratie in het 
gecreëerde botdefect. Bovendien namen we waar dat anti-
osteoporotische medicatie, d.w.z. BPs, botregeneratie gunstig kan 
ondersteunen afhankelijk van de toegediende dosis en ook de timing 
van het toedienen.
Verstoorde botregeneratie in osteoporotische condities.
In een normale metabolische conditie, vindt botregeneratie plaats 
door middel van een goed gebalanceerde activiteit en precieze 
coördinatie van osteoblasts en osteoclasts. Verstoorde 
botregeneratie/metabolisme wordt vaak geassocieerd met het 
plaatsvinden van een pathologische botziekte zoals osteoporose. 
Ondanks de beschikbare kennis over osteoporose, is de invloed 
daarvan op botregeneratie gerelateerd aan bottransplantatie nog 
steeds niet helemaal duidelijk. Bovendien is er geen informatie 
beschikbaar over hoe osteoporose botregeneratie beïnvloedt in 
getransplanteerde defecten indien osteoporose begint na het 
installeren van de transplantatie. Zoals vermeld in hoofdstuk 2, dat 
het toebrengen van een osteoporotische conditie in preklinische 
dieren na het eerste genezen van bottransplantatiemateriaal een 
negatieve invloed heeft op botregeneratie in het gecreëerde 




onderzoek. Het precieze onderliggende biologische mechanisme van 
deze resultaten werd echter niet onderzocht. Meer kennis over het 
betrokken pathofysiologisch proces gerelateerd aan botregeneratie in 
en kunstmatig gecreëerd botdefect is vereist, aangezien onze 
observaties in Hoofdstukken 4 en 5 aantoonden dat het ongunstige 
effect van osteoporose ongedaan kan worden gemaakt door het 
toedienen van anti-osteoporotische medicatie. De invloed van deze 
middelen echter is afhankelijk van het type, de dosering en de timing 
van het toedienen. Daarom worden diepgaande cellulaire en 
moleculaire onderzoeken aanbevolen om de kenmerkende 
eigenschappen van osteoporose gerelateerd aan het genezen van 
botdefecten te verkennen. Dergelijk onderzoek is ook erg relevant wat 
betreft het potentieel en veilig klinisch toedienen van anti-
osteoporotische medicatie in bottransplantaties in osteoporotische 
condities.
Kenmerken van een ideale botsubstituut voor 
botregeneratie.
Klinisch gezien, kunnen enkele manieren van botregeneratie worden 
toegepast om benige defecten met succes te behandelen. Het ideale 
botsubsituut dient echter geen negatieve immuunreactie op te roepen. 
Bovendien moeten ze in staat zijn hun volume te behouden over een 
voorspelbare tijdsperiode, maar moeten na verloop van tijd verdwijnen 
om negatieve effecten op de mechanische eigenschappen van het 
geregenereerde bot te voorkomen [5]. Daarom moet 
botsubtitutiemateriaal een goed gecontroleerde biologische 
afbreekbaarheid hebben. Een andere cruciale eigenschap voor ideaal 
bottransplantatiemateriaal is dat het angiogenese moet opwekken 
voor het reguleren van botvorming [6]. Het is bekend dat zuurstof en 
de aanwezigheid van angiogene factoren effect hebben op botcellen 
181
Summary, Closing Remarks, and Future Perspectives
6
en nodig zijn voor het succesvol genezen van bot. Bovendien dienen 
botsubstituten niet duur te zijn. Helaas, hebben geen van de op dit 
moment beschikbaare botsubstitutiemterialen al deze gewenste 
eigenschappen. Niettemin, de problemen geassocieerd met menselijk 
getransplanteerd bottransplantatie hebben het gebruiken van 
xenotransplantatie doen toenemen (bijvoorbeeld boviene botdeeltjes) 
en synthetische botsubstituten (bijvoorbeeld bate calciumfosfaat, 
ß-TCP). Zoals bevestigd door onze histologische en 
histomorphometrische evaluaties in hoofdstukken 2, 4 en 5, had het 
gebruikt biomateriaal inderdaad geen negatief effect op de 
regeneratie van de gecreëerde botdefecten. Aan de andere kant, ze 
hadden geen aanvullende bevorderend botvormingseffect in de 
aanwezigheid van een osteoporotische conditie. Wat dit betreft, onze 
resultaten ondersteunen de vereiste dat bottransplantatiemateriaal 
regeneratieve capaciteiten moet uitlokken. Een dergelijke 
bevorderende rol van botvorming is erg relevant voor patiënten met 
onderliggende botziekten om de tijd van het genezen te reduceren en 
de uitkomst van het genezingsproces beter voorspelbaar te maken. 
Naast de structurele toediening van anti-osteoporotische middelen, 
raden wij aan nog meer onderzoek uit te voeren naar de mogelijkheid 
van het integreren van deze medicijnen in botsubstitutiemateriaal en 
hun effect na locale toediening.
Farmacologische verbetering van botaugmentatie.
Onderzoek uitgevoerd in de huidige these heeft het significante 
therapeutische potentieel van anti-osteoporotische medicatie voor het 
genezen van bottransplantatie in een osteoporotische conditie 
aangetoond. De klinisch toegepaste anti-osteoporotische medicijnen 




anabolische middelen (bijvoorbeeld Simvastatine). Een van de meest 
voorkomende bifosfonaten, alendronaat en zoledronaat werden 
gebruikt in hoofdstuk 4 en 5 om in vivo botvorming te stimuleren in 
combinatie met botsubstituten. Hoewel de werking van hun 
moleculaire mechanismen niet helemaal duidelijk is, zijn deze 
medicijnen oorspronkelijk bedoeld om het botverlies in 
osteoporotische conditie om te keren door het botmetabolisme te 
wijzigen. Zoals echter vermeld in het bovenstaande, was het 
achterhalen van de factoren van metabolisch botaandoeningen en de 
specifieke pathofysiologische mechanismen ervan niet het doel van de 
huidige these. Daarom raden we aan dat op een toekomstige wijze 
enkele kwesties gerelateerd aan het handelingsmechanisme van BPs 
met betrekking tot transplantaties met botsubstituten worden 
opgelost vóór dat er wordt begonnen met klinisch testen.
Wat interessant is, is dat de gecombineerde therapie (Alendronaat 
plus Simvastatine) in combinatie met bottransplantie eveneens leidde 
tot een significante toename in botregeneratie in osteoporotische 
condities gebaseerd op onze histologische evaluatie (hoofdstuk 4). 
Voor een succesvolle klinische toepassing, geldt dat het belangrijk is 
te overwegen dat dergelijke observaties afhankelijk zijn van het 
doseerregieme en de regelmaat van het toedienen van medicatie, de 
farmacokinetiek van de medicatie, de grootte van het botdefect en 
ook het type botsubstituut en de regeneratieve capaciteit ervan. Deze 
biologische en materiële kwesties dienen in de toekomst te worden 
onderzocht en gevalideerd vóór de klinische inzet van de huidige 
resultaten van de these.
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In vivo experimenteel model en beperkingen.
Experimenten uitgevoerd op specimen zoals konijnen, geiten, schapen, 
honden en knaagdieren worden vaak gebruikt om botregeneratie te 
bestuderen. Voor het nabootsen van osteoporotische botcondities 
werden in de huidige these ratten gebruikt om wijzigingen in 
botregeneratie te stimuleren na ingebrachte oestrogene aandoening 
zoals bij mensen. Hoewel ratten kleine experimentele dieren zijn, en in 
vergelijking met mensen, een afwijkende botvorming en 
hermodelleringssnelheid hebben, zijn het uitstekende preklinische 
modellen voor het besturderen van osteoporotische veranderingen 
omdat ze nauwgezet farmacotherapeutische reacties emuleren en het 
bestuderen van het effect van de uitputting van oestrogeen op het 
skelet mogelijk maken [7].
Tijdens onze verschillende experimenten, waren we in staat om het 
effect van anti-osteoporotisch medicatie op botregeneratie 
gerelateerd aan bottransplantatie in een directe vergelijking te 
bestuderen door zowel dieren met osteoporotische condities en 
gezonde dieren in één enkel onderzoek te gebruiken. Er moet echter 
worden opgemerkt dat het preklinische model zoals dat werd gebruik 
in de huidige these te maken heeft met enkele beperkingen die in 
toekomstig onderzoek moeten worden opgelost. Er werd bijvoorbeeld 
waargenomen dat ratten waarvan de eierstokken werden weggehaald 
een sneller botomzet hebben dan patiënten met osteoporose. 
Bovendien voerden wij onderzoek van een korte duur uit, terwijl het op 
de lange termijn op peil houden van het gunstige effect van de 
medicatie belangrijk is voor veilige klinische toepassing. Daarom kan 
verder in vivo onderzoek worden voorgesteld om het effect van het op 




botregeneratie gerelateerd aan verschillende botsubstituten te 
valideren. Ter aanvulling, een groter diermodel dient te worden 
gebruikt om het effect van anti-osteoporotisch medicatie in 
combinatie met bottransplanatie onder slechte botcondities te 
verduidelijken.
Bovendien moeten we benadrukken dat de experimentele 
osteoporotische ratten in de huidige these voornamelijk werden 
gevoed met een dieet met een hoog calcium gehalte, iets dat 
(gedeeltelijk) de conditie van osteopenie in dieren waaruit de 
eierstokken werden verwijderd [8].
Ons doel was het nabootsen van de klinische conditie, aangezien 
osteoporotische patiënten gewend zijn aan het eten van gezond eten 
met voldoende hoeveelheden calcium en vitamine D. Niettemin, het 
effect van voeding moet sterk worden overwogen in toekomstige 
pogingen tot onderzoek.
Ten slotte, er wordt verwacht dat het biologische voordeel van anti-
osteoporotische medicatie op botregeneratie verminderd wordt door 
het type transplantatiemateriaal (natuurlijk versus synthetisch) en hun 
chemisch compositie en degradatie. De aard en karakteristieken van 
het gebruikt bottransplantatiemateriaal echter was niet de focus in de 
vergelijkende analyse in het huidig onderzoek. Deze kwestie 
rechtvaardigt meer in vivo onderzoek in de individuele effecten van 
verschillend botsubstitutiemateriaal naast anti-osteoporotische 
medicatie in gezonde en osteoporotische diermodellen.
Samenvattend, onze experimenten gaven aan dat het toedienen van 
BPs het genezingsproces van botdefecten in de aanwezigheid van een 
osteoporotische conditie kan ondersteunen. Dit effect is echter 
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afhankelijk van de juiste dosis en de timing van het toedienen van BP. 
Ondanks deze gunstige uitkomst, had ons onderzoek enkele 
beperkingen die verder moeten worden onderzocht voordat onze 
gegevens kunnen worden omgezet naar klinisch toepassing op 
mensen. 
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